Romosozumab (AMG 785) in Postmenopausal Women With Low Bo... | NCT00896532 | Trialant
NCT00896532
Sponsor
Amgen
Status
Completed
Last Update Posted
Sep 22, 2022Actual
Enrollment
419Actual
Phase
Phase 2
Conditions
Low Bone Mineral Density
Postmenopausal Osteoporosis
Interventions
Placebo to Romosozumab
Alendronate
Teriparatide
Romosozumab
Denosumab
Placebo to Denosumab
Zoledronic acid
Countries
Not provided
Protocol Section
Identification Module
NCT ID
Results Section
Participant Flow Module
Pre-assignment Details
Annotation Section
No data available
No data is available for this block.
Document Section
No data available
No data is available for this block.
Derived Section
Miscellaneous Info Module
Version Holder
NCT00896532
Obsolete or Duplicate NCT IDs
Not provided
Organization Study
20060326
Secondary IDs
ID
Type
Description
Link
2008-005991-28
EudraCT Number
Brief Title
Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density
Official Title
A Randomised, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 785 in the Treatment of Postmenopausal Women With Low Bone Mineral Density
Acronym
Not provided
Organization
AmgenINDUSTRY
Status Module
Record Verification Date
Sep 2022
Overall Recruitment Status or Expanded Access Status
Completed
Last Known Status
Not provided
Delayed Posting
Not provided
Why Stopped
Not provided
Expanded Access Info
No
Start Date
Jun 3, 2009Actual
Primary Completion Date
Feb 21, 2011Actual
Completion Date
Feb 18, 2016Actual
First Submitted Date
May 7, 2009
First Submission Date that Met QC Criteria
May 7, 2009
First Posted Date
May 11, 2009Estimated
Results Waived
Not provided
Results First Submitted Date
Nov 20, 2018
Results First Submitted that Met QC Criteria
Nov 20, 2018
Results First Posted Date
Dec 14, 2018Actual
Certification/Extension (aka Delayed Results) First Submitted Date
Apr 16, 2013
Certification/Extension First Submitted that Passed QC Review
Apr 16, 2013
Certification/Extension First Posted Date
Apr 24, 2013Estimated
Last Update Submitted Date
Sep 9, 2022
Last Update Posted Date
Sep 22, 2022Actual
Sponsor/Collaborators Module
Responsible Party, by Official Title
Sponsor
Lead Sponsor
AmgenINDUSTRY
Collaborators
Not provided
Oversight Module
Has Data Monitoring Committee (DMC)
No
Is FDA Regulated Drug
Not provided
Is FDA Regulated Device
Not provided
Is Unapproved Device
Not provided
Pediatric Postmarket Surveillance of a Device Product
Not provided
Product Exported from US
Not provided
FDAAA801 Violation
Not provided
Description Module
Brief Summary
The primary objective was to determine the effect of treatment with romosozumab versus placebo at month 12 on the percent change from baseline in bone mineral density (BMD) at the lumbar spine in postmenopausal women with low bone density.
Detailed Description
This study included a 24-month treatment phase followed by rerandomization to a 12-month extension phase with denosumab or placebo, followed by a 12-month retreatment phase with romosozumab, followed by a 24-month follow-on phase with zoledronic acid or no intervention.
24-month Romosozumab Treatment Phase (months 1 to 24): Participants were randomized in a 1:1:1:1:1:1:1:1 ratio to receive 1 of 5 double-blind dosing regimens of romosozumab or placebo or open-label alendronate (ALN) or open-label teriparatide (TPTD) for the first 12 months of the study. At month 12, participants in the romosozumab and placebo groups continued their assigned treatment for an additional 12 months, participants in the TPTD group ended study participation, and participants in the ALN group transitioned to receive romosozumab 140 mg subcutaneously (SC) every month (QM) for an additional 12 months (months 12 to 24).
12-month Denosumab Extension Phase (months 24 to 36): At the end of the 24-month romosozumab treatment phase, eligible participants were randomized 1:1 within their original treatment group to receive either denosumab or placebo every 6 months (Q6M) for 12 months.
12-month Romosozumab Retreatment Phase (months 36 to 48): From months 36 to 48, participants initially randomized to romosozumab or placebo received romosozumab 210 mg SC QM. Participants who initially received ALN ended their participation at month 36 and were not retreated with romosozumab.
24-month Follow-on Phase (months 48 to 72): At month 48, participants received 1 dose of zoledronic acid 5 mg intravenously or no intervention for an additional 24 months.
Conditions Module
Conditions
Low Bone Mineral Density
Postmenopausal Osteoporosis
Keywords
Not provided
Design Module
Study Type
Interventional
Number of References to an Expanded Access Study
Not provided
Expanded Access Types
Not provided
Patient Registry
Not provided
Target Follow-Up Duration
Not provided
Phases
Phase 2
Interventional Study Design
Allocation
Biospecimen
No data available
No data is available for this block.
Enrollment
419Actual
Arms/Interventions Module
Arm Groups
Label
Type
Description
Intervention Names
Placebo
Placebo Comparator
Participants received placebo matching to romosozumab once a month (QM) or once every 3 months (Q3M) administered subcutaneously (SC) for up to 24 months.
Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention.
Drug: Placebo to Romosozumab
Drug: Denosumab
Drug: Placebo to Denosumab
Drug: Zoledronic acid
Alendronate
Active Comparator
Participants received open-label alendronate (ALN) 70 mg orally (PO) every week (QW) for 12 months. At month 12 participants transitioned to receive romosozumab 140 mg subcutaneously every month for an additional 12 months (months 12 to 24).
Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. At month 36 participants ended study participation.
Drug: Alendronate
Drug: Romosozumab
Drug: Denosumab
Drug: Placebo to Denosumab
Teriparatide
Active Comparator
Participants received open-label teriparatide 20 μg subcutaneously every day (QD) for 12 months. At month 12 participants ended study participation.
Drug: Teriparatide
Romosozumab 70 mg QM
Experimental
Participants received double-blind romosozumab 70 mg subcutaneously every month for 24 months.
Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention.
Interventions
Name
Type
Description
Arm Group Labels
Other Names
Placebo to Romosozumab
Drug
Administered by subcutaneous injection QM or Q3M.
Placebo
Outcomes Module
Primary Outcomes
Measure
Description
Time Frame
Percent Change From Baseline at Month 12 in BMD at the Lumbar Spine
Bone mineral density was measured using dual energy x-ray absorptiometry (DXA). Images were analyzed by a central imaging reader.
Baseline to 12 months
Secondary Outcomes
Measure
Description
Time Frame
Percent Change From Baseline at Month 6 in BMD at the Lumbar Spine
Bone mineral density was measured using dual energy x-ray absorptiometry (DXA). Images were analyzed by a central imaging reader.
Percent change from baseline to month 6 was analyzed using a linear mixed effects model with the percent change from baseline to month 6 in DXA BMD as dependent variable, and baseline BMD value, machine type, geographic region, interaction of baseline BMD and machine type, visit, treatment (categorical) and interaction of treatment and visit as the independent variables.
Other Outcomes
Not provided
Eligibility Module
Eligibility Criteria
Inclusion Criteria:
Ambulatory, postmenopausal women, aged ≥ 55 to ≤ 85
Low BMD measured by dual energy X-ray absorptiometry (DXA) and assessed by the central imaging vendor (equivalent to T-scores between -2.0 and -3.5)
Exclusion Criteria:
History of vertebral fracture, or fragility fracture of the wrist, humerus, hip or pelvis after age 50
Untreated hyper- or hypothyroidism
Current hyper- or hypoparathyroidism, hypo- or hypercalcemia
Elevated transaminases
Significantly impaired renal function
Positive for: human immunodeficiency virus (HIV), hepatitis-C or hepatitis-B surface antigen
Malignancy
History of solid organ or bone marrow transplants
Use of agents affecting bone metabolism
Contraindicated or intolerant of alendronate therapy
Contraindicated or intolerant of teriparatide therapy
Inclusion Criteria for the 12 month extension phase (Month 24 to 36):
- Normocalcemia at or after the Month 21 visit but before the Month 24 study visit
Exclusion Criteria for the 12 month extension phase (Month 24 to 36)
Incidence of a clinical vertebral fracture or fragility fracture of the wrist, humerus, hip or pelvis during the initial 24 month treatment phase of the study
A BMD loss of ≥ 7.0% from baseline at any time up to the Month 18 visit of the initial 24-month treatment phase
Malignancy
History of osteonecrosis of the jaw
Use of proscribed medication during the initial 24 month treatment phase
Contraindicated or intolerant of denosumab therapy
Inclusion Criteria for the 12 month re-treatment phase (Month 36 to 48)
Albumin adjusted serum calcium of the most recent blood draw at or after the Month 30 visit but before the Month 36 study visit. Calcium repletion is permitted and central laboratory analysis of albumin adjusted serum calcium may be repeated before the Month 36 study visit
Participation in Group A or B during initial 24 month treatment phase
Subject has reached M36 of the study
Appropriate written informed consent must be obtained
Exclusion Criteria for the 12 month re-treatment phase (Month 36 to 48)
New malignancy
Use of proscribed medication during the 12 month extension phase
Inclusion Criteria for the 24 month follow-on phase (Month 48 to 72) General inclusion criteria for participation
Subject has reached month 48 of the study
Appropriate written informed consent must be obtained Inclusion criteria for assignment to the no intervention group
During the 24 month AMG 785 treatment phase, subject was assigned to any AMG 785 treatment group
During the 12 month denosumab extension phase, subject was assigned to the denosumab treatment group Exclusion for the 24 month follow-on phase (Month 48 to 72)
New malignancy
Use of proscribed meds during the 12 month re-treatment phase
Partial informed consent withdrawal and discontinuation of investigational product at any time up to month 48 visit
Incidence of a clinical vertebral fracture or fragility fracture of the wrist, humerus, hip or pelvis during the initial 24 month treatment phase of the study
BMD T-score of ≤ -2.5 at the lumbar spine, total hip, or femoral neck based on local read of the DXA scans at month 48
Genant HK, Engelke K, Bolognese MA, Mautalen C, Brown JP, Recknor C, Goemaere S, Fuerst T, Yang YC, Grauer A, Libanati C. Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass. J Bone Miner Res. 2017 Jan;32(1):181-187. doi: 10.1002/jbmr.2932. Epub 2016 Sep 20.
A total of 807 patients were screened and 419 were randomized. The study included a 24-month treatment phase, followed by rerandomization to a 12-month extension phase with denosumab or placebo; followed by a 12-month retreatment phase with romosozumab, followed by a 24-month follow-on phase with zoledronic acid or no intervention.
Recruitment Details
This study was conducted at 29 centers in 7 countries in Europe, North America, and Argentina. Participants were enrolled from the 3rd of June 2009 to the 17th of February 2010.
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
FG000
Placebo
Participants received placebo matching to romosozumab once a month (QM) or once every 3 months (Q3M) administered subcutaneously for 24 months.
FG001
Alendronate
Participants received open-label alendronate (ALN) 70 mg orally (PO) every week (QW) for 12 months. At month 12 participants transitioned to receive romosozumab 140 mg subcutaneously every month for an additional 12 months (months 12 to 24).
FG002
Teriparatide
Participants received open-label teriparatide 20 μg subcutaneously every day (QD) for 12 months. At month 12 participants ended study participation.
FG003
Romosozumab 70 mg QM
Participants received double-blind romosozumab 70 mg subcutaneously every month for 24 months.
FG004
Romosozumab 140 mg Q3M
Participants received double-blind romosozumab 140 mg subcutaneously once every 3 months for 24 months.
FG005
Romosozumab 140 mg QM
Participants received double-blind romosozumab 140 mg QM subcutaneously for 24 months.
FG006
Romosozumab 210 mg Q3M
Participants received double-blind romosozumab 210 mg Q3M subcutaneously for 24 months.
FG007
Romosozumab 210 mg QM
Participants received double-blind romosozumab 210 mg QM subcutaneously for 24 months.
FG008
Month 24-36: Placebo/Placebo
Participants who received placebo in the 24-month romosozumab treatment phase then received placebo to denosumab subcutaneously once every 6 months (Q6M) for 12 months during the denosumab extension phase.
FG009
Month 24-36: Placebo/Denosumab
Participants who received placebo in the 24-month romosozumab treatment phase then received denosumab 60 mg subcutaneously once every 6 months for 12 months during the denosumab extension phase.
FG010
Month 24-36: Alendronate/Romosozumab/Placebo
Participants who received alendronate for the first 12 months and romosozumab 140 mg subcutaneously every month from months 12 to 24 received placebo to denosumab subcutaneously once every 6 months for 12 months during the denosumab extension phase.
FG011
Month 24-36: Alendronate/Romosozumab/Denosumab
Participants who received alendronate for the first 12 months, romosozumab 140 mg subcutaneously QM from months 12 to 24 received denosumab 60 mg subcutaneously once every 6 months for 12 months during the denosumab extension phase.
FG012
Month 24-36: Romosozumab/Placebo
Participants who received romosozumab at any dose for 24 months in the romosozumab treatment phase received placebo to denosumab subcutaneously once every 6 months for 12 months during the denosumab extension phase.
FG013
Month 24-36: Romosozumab/Denosumab
Participants who received romosozumab at any dose for 24 months in the romosozumab treatment phase received denosumab 60 mg subcutaneously once every 6 months for 12 months during the denosumab extension phase.
FG014
Month 36-48: Placebo/Placebo/Romosozumab
Participants who received placebo in the first 24-month romosozumab treatment phase and placebo to denosumab during months 24-36 then received romosozumab 210 mg subcutaneously QM in the 12-month romosozumab retreatment phase (months 36 to 48).
FG015
Month 36-48: Placebo/Denosumab/Romosozumab
Participants who received placebo in the first 24 month romosozumab treatment phase and denosumab 60 mg during months 24 to 36 then received romosozumab 210 mg subcutaneously QM in the 12-month romosozumab retreatment phase (months 36 to 48).
FG016
Month 36-48: Romosozumab/Placebo/Romosozumab
Participants who received romosozumab at any dose during the first 24-month romosozumab treatment phase and placebo to denosumab during months 24 to 36 then received romosozumab 210 mg subcutaneously QM in the 12-month romosozumab retreatment phase (months 36 to 48).
FG017
Month 36-48: Romosozumab/Denosumab/Romosozumab
Participants who received romosozumab at any dose during the first 24-month romosozumab treatment phase and denosumab 60 mg during months 24 to 36 then received romosozumab 210 mg subcutaneously QM in the 12-month romosozumab retreatment phase (months 36 to 48).
Participants who received romosozumab at any dose during the 24-month romosozumab treatment phase, denosumab 60 mg during months 24 to 36 and romosozumab 210 mg QM in months 36 to 48 then received no intervention during the 24-month follow-on phase (months 48-72).
Participants who received placebo in the 24-month romosozumab treatment phase, placebo to denosumab during months 24 to 36 and romosozumab 210 mg QM in months 36 to 48 then received a single dose of open-label zoledronic acid 5 mg intravenously at month 48.
Participants who received placebo in the 24-month romosozumab treatment phase, denosumab 60 mg Q6M from months 24 to 36 and romosozumab 210 mg QM from months 36 to 48 then received a single dose of open-label zoledronic acid 5 mg intravenously at month 48.
Participants who received romosozumab at any dose during the 24-month romosozumab treatment phase, placebo to denosumab during months 24 to 36 and romosozumab 210 mg QM in months 36 to 48 then received a single dose of open-label zoledronic acid 5 mg intravenously at month 48.
Participants who received romosozumab at any dose during the 24-month romosozumab treatment phase, denosumab 60 mg Q6M during months 24 to 36 and romosozumab 210 mg QM in months 36 to 48 then received a single dose of open-label zoledronic acid 5 mg intravenously at month 48.
Periods
Title
Milestones
Reasons Not Completed
Months 1-24: Romosozumab Treatment Phase
Type
Comment
Milestone Data
STARTED
FG00052 subjects
FG00151 subjects
FG00255 subjects
FG00351 subjects
FG004
Received Treatment
FG00051 subjectsOne participant received 1 dose of romosozumab 70 mg in error
FG00151 subjects
FG00254 subjects
FG00349 subjects
Completed 12 Months
FG00047 subjects
FG00149 subjects
FG00246 subjects
FG00345 subjects
FG004
COMPLETED
FG00046 subjects
FG00145 subjects
FG00246 subjects
FG00339 subjects
FG004
NOT COMPLETED
FG0006 subjects
FG0016 subjects
FG0029 subjects
FG00312 subjects
FG004
Type
Comment
Reasons
Protocol Deviation
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG003
Months 24-36: Denosumab Extension Phase
Type
Comment
Milestone Data
STARTED
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG003
Months 36-48: Romosozumab Retreatment
Type
Comment
Milestone Data
STARTED
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG003
Months 48-72: Follow-on Phase
Type
Comment
Milestone Data
STARTED
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG003
Baseline Characteristics Module
Baseline Analysis Population Description
All randomized participants (full analysis set)
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
BG000
Placebo
Participants received placebo matching to romosozumab once a month (QM) or once every 3 months (Q3M) administered subcutaneously for 24 months.
BG001
Alendronate
Participants received open-label alendronate (ALN) 70 mg orally (PO) every week (QW) for 12 months. At month 12 participants transitioned to receive romosozumab 140 mg subcutaneously every month for an additional 12 months (months 12 to 24).
Denominators
Units
Counts
Participants
BG000
Baseline Measures
Title
Description
Population Description
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Denominator Units Selected
Denominators
Classes
Age, Continuous
Mean
Outcome Measures Module
Outcome Measures
Type
Title
Description
Population Description
Reporting Status
Anticipated Posting Date
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Time Frame
Units Analyzed
Denominator Units Selected
Arm/Group Information
Denominators
Classes
Analyses
Primary
Percent Change From Baseline at Month 12 in BMD at the Lumbar Spine
Bone mineral density was measured using dual energy x-ray absorptiometry (DXA). Images were analyzed by a central imaging reader.
All randomized participants who had non-missing baseline and month 12 measurements.
Posted
Least Squares Mean
95% Confidence Interval
percent change
Baseline to 12 months
ID
Title
Description
OG000
Placebo
Participants received placebo matching to romosozumab once a month (QM) or once every 3 months (Q3M) administered subcutaneously for 24 months.
OG001
Alendronate
Participants received open-label alendronate (ALN) 70 mg orally (PO) every week (QW) for 12 months. At month 12 participants transitioned to receive romosozumab 140 mg subcutaneously every month for an additional 12 months (months 12 to 24).
Adverse Events Module
Frequency Threshold
5
Time Frame
Adverse events are reported by treatment phase: Romosozumab treatment phase (Baseline [BL] to month 12 and 24); Denosumab extension phase (months 24 to 36); Romosozumab retreatment phase (months 36 to 48); Follow-on phase (months 48 to 72).
Description
The safety subset is based on actual treatment received. One participant randomized to placebo received 1 dose of romosozumab 70 mg in error was subsequently randomized to denosumab and then received romosozumab in the retreatment phase. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed a 5% threshold
All-Cause Mortality Comment
Not provided
Arm/Groups
ID
Title
Description
Deaths (Affected)
Deaths (At Risk)
Serious Events (Affected)
Serious Events (At Risk)
Other Events (Affected)
Other Events (At Risk)
EG000
BL-Month 12: Placebo QM
Participants received placebo matching to romosozumab once a month (QM) administered subcutaneously for 12 months.
Participants received double-blind romosozumab 140 mg subcutaneously once every 3 months for 24 months.
Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention.
Drug: Romosozumab
Drug: Denosumab
Drug: Placebo to Denosumab
Drug: Zoledronic acid
Romosozumab 140 mg QM
Experimental
Participants received double-blind romosozumab 140 mg QM subcutaneously for 24 months.
Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention.
Drug: Romosozumab
Drug: Denosumab
Drug: Placebo to Denosumab
Drug: Zoledronic acid
Romosozumab 210 mg Q3M
Experimental
Participants received double-blind romosozumab 210 mg Q3M subcutaneously for 24 months.
Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention.
Drug: Romosozumab
Drug: Denosumab
Drug: Placebo to Denosumab
Drug: Zoledronic acid
Romosozumab 210 mg QM
Experimental
Participants received double-blind romosozumab 210 mg QM subcutaneously for 24 months.
Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention.
Drug: Romosozumab
Drug: Denosumab
Drug: Placebo to Denosumab
Drug: Zoledronic acid
Alendronate
Drug
Administered orally once a week
Alendronate
Fosamax
Teriparatide
Drug
Teriparatide 20 μg administered by subcutaneous injection once a day
Teriparatide
Forsteo
Romosozumab
Drug
Administered by subcutaneous injection
Alendronate
Romosozumab 140 mg Q3M
Romosozumab 140 mg QM
Romosozumab 210 mg Q3M
Romosozumab 210 mg QM
Romosozumab 70 mg QM
AMG 785
EVENITYâ„¢
Denosumab
Drug
Denosumab 60 mg administered by subcutaneous injection Q6M
Alendronate
Placebo
Romosozumab 140 mg Q3M
Romosozumab 140 mg QM
Romosozumab 210 mg Q3M
Romosozumab 210 mg QM
Romosozumab 70 mg QM
Prolia®
Placebo to Denosumab
Drug
Administered by subcutaneous injection Q6M
Alendronate
Placebo
Romosozumab 140 mg Q3M
Romosozumab 140 mg QM
Romosozumab 210 mg Q3M
Romosozumab 210 mg QM
Romosozumab 70 mg QM
Zoledronic acid
Drug
Zoledronic acid 5 mg administered intravenously
Placebo
Romosozumab 140 mg Q3M
Romosozumab 140 mg QM
Romosozumab 210 mg Q3M
Romosozumab 210 mg QM
Romosozumab 70 mg QM
Aclasta
Baseline to 6 months
Percent Change From Baseline at Month 6 in BMD of the Total Hip
Bone mineral density was measured using dual energy x-ray absorptiometry (DXA). Images were analyzed by a central imaging reader.
Percent change from baseline to month 6 was analyzed using a linear mixed effects model with the percent change from baseline to month 6 in DXA BMD as dependent variable, and baseline BMD value, machine type, geographic region, interaction of baseline BMD and machine type, visit, treatment (categorical) and interaction of treatment and visit as the independent variables.
Baseline to 6 months
Percent Change From Baseline at Month 6 in BMD of the Femoral Neck
Bone mineral density was measured using dual energy x-ray absorptiometry (DXA). Images were analyzed by a central imaging reader.
Percent change from baseline to month 6 was analyzed using a linear mixed effects model with the percent change from baseline to month 6 in DXA BMD as dependent variable, and baseline BMD value, machine type, geographic region, interaction of baseline BMD and machine type, visit, treatment (categorical) and interaction of treatment and visit as the independent variables.
Baseline to 6 months
Percent Change From Baseline at Month 12 in BMD of the Total Hip
Bone mineral density was measured using dual energy x-ray absorptiometry (DXA). Images were analyzed by a central imaging reader.
Percent change from baseline to 12 months in BMD was analyzed using a linear mixed effects model with the percent change from baseline to month 12 in DXA BMD as dependent variable, and baseline BMD value, machine type, geographic region, interaction of baseline BMD and machine type, visit, treatment (categorical) and interaction of treatment and visit as the independent variables.
Baseline to 12 months
Percent Change From Baseline at Month 12 in BMD of the Femoral Neck
Bone mineral density was measured using dual energy x-ray absorptiometry (DXA). Images were analyzed by a central imaging reader.
Percent change from baseline to 12 months in BMD was analyzed using a linear mixed effects model with the percent change from baseline to month 12 in DXA BMD as dependent variable, and baseline BMD value, machine type, geographic region, interaction of baseline BMD and machine type, visit, treatment (categorical) and interaction of treatment and visit as the independent variables.
Baseline to 12 months
Percent Change From Baseline at Month 12 in BMD of the Distal Radius
Bone mineral density was measured using dual energy x-ray absorptiometry (DXA). Images were analyzed by a central imaging reader.
Percent change from baseline in distal radius BMD was analyzed using an analysis of covariance (ANCOVA) model with the percent change from baseline to Month 12 in DXA BMD as dependent variable, baseline BMD value, machine type, interaction of baseline BMD and machine type, treatment (categorical) and geographic region as the independent class variables.
Baseline to 12 months
Percent Change From Baseline in Procollagen Type 1 N-telopeptide (P1NP)
Percent change from baseline in the bone turnover marker (BTM) P1NP was analyzed using a linear mixed effects model with the natural logarithm of the ratio of BTM (follow-up versus baseline) as the dependent variables, and visit, treatment (categorical), interaction of treatment and visit and the natural logarithm of the baseline BTM as the independent variables; outcomes were then transformed back to percent change from baseline.
Baseline and months 1, 3, 6, 9, and 12
Percent Change From Baseline in Type 1 Collagen C-telopeptide (CTX)
Percent change from baseline in the bone turnover marker (BTM) CTX was analyzed using a linear mixed effects model with the natural logarithm of the ratio of BTM (follow-up versus baseline) as the dependent variables, and visit, treatment (categorical), interaction of treatment and visit and the natural logarithm of the baseline BTM as the independent variables; outcomes were then transformed back to percent change from baseline.
Baseline and months 1, 3, 6, 9, and 12
Percent Change From Baseline in Osteocalcin
Percent change from baseline in the bone turnover marker (BTM) osteocalcin was analyzed using a linear mixed effects model with the natural logarithm of the ratio of BTM (follow-up versus baseline) as the dependent variables, and visit, treatment (categorical), interaction of treatment and visit and the natural logarithm of the baseline BTM as the independent variables; outcomes were then transformed back to percent change from baseline.
Baseline and months 1, 3, 6, 9, and 12
Percent Change From Baseline in Bone-specific Alkaline Phosphatase (BSAP)
Percent change from baseline in the bone turnover marker (BTM) BSAP was analyzed using a linear mixed effects model with the natural logarithm of the ratio of BTM (follow-up versus baseline) as the dependent variables, and visit, treatment (categorical), interaction of treatment and visit and the natural logarithm of the baseline BTM as the independent variables; outcomes were then transformed back to percent change from baseline.
Baseline and months 1, 3, 6, 9, and 12
Background
Keaveny TM, Crittenden DB, Bolognese MA, Genant HK, Engelke K, Oliveri B, Brown JP, Langdahl BL, Yan C, Grauer A, Libanati C. Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass. J Bone Miner Res. 2017 Sep;32(9):1956-1962. doi: 10.1002/jbmr.3176. Epub 2017 Jun 26.
Kendler DL, Bone HG, Massari F, Gielen E, Palacios S, Maddox J, Yan C, Yue S, Dinavahi RV, Libanati C, Grauer A. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab. Osteoporos Int. 2019 Dec;30(12):2437-2448. doi: 10.1007/s00198-019-05146-9. Epub 2019 Oct 18.
McClung MR, Brown JP, Diez-Perez A, Resch H, Caminis J, Meisner P, Bolognese MA, Goemaere S, Bone HG, Zanchetta JR, Maddox J, Bray S, Grauer A. Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study. J Bone Miner Res. 2018 Aug;33(8):1397-1406. doi: 10.1002/jbmr.3452. Epub 2018 May 22.
McClung MR, Bolognese MA, Brown JP, Reginster JY, Langdahl BL, Maddox J, Shi Y, Rojeski M, Meisner PD, Grauer A. A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab. Osteoporos Int. 2020 Nov;31(11):2231-2241. doi: 10.1007/s00198-020-05502-0. Epub 2020 Jul 4.
McClung MR, Bolognese MA, Brown JP, Reginster JY, Langdahl BL, Shi Y, Timoshanko J, Libanati C, Chines A, Oates MK. Skeletal responses to romosozumab after 12 months of denosumab. JBMR Plus. 2021 Jun 3;5(7):e10512. doi: 10.1002/jbm4.10512. eCollection 2021 Jul.
Poole KE, Treece GM, Pearson RA, Gee AH, Bolognese MA, Brown JP, Goemaere S, Grauer A, Hanley DA, Mautalen C, Recknor C, Yang YC, Rojeski M, Libanati C, Whitmarsh T. Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density. J Bone Miner Res. 2022 Feb;37(2):256-264. doi: 10.1002/jbmr.4465. Epub 2021 Dec 16.
McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014 Jan 30;370(5):412-20. doi: 10.1056/NEJMoa1305224. Epub 2014 Jan 1.
54 subjects
FG00551 subjects
FG00653 subjects
FG00752 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG0140 subjects
FG0150 subjects
FG0160 subjects
FG0170 subjects
FG0180 subjects
FG0190 subjects
FG0200 subjects
FG0210 subjects
FG0220 subjects
FG00453 subjects
FG00548 subjects
FG00653 subjects
FG00751 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG0140 subjects
FG0150 subjects
FG0160 subjects
FG0170 subjects
FG0180 subjects
FG0190 subjects
FG0200 subjects
FG0210 subjects
FG0220 subjects
50 subjects
FG00546 subjects
FG00651 subjects
FG00749 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG0140 subjects
FG0150 subjects
FG0160 subjects
FG0170 subjects
FG0180 subjects
FG0190 subjects
FG0200 subjects
FG0210 subjects
FG0220 subjects
46 subjects
FG00543 subjects
FG00648 subjects
FG00748 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG0140 subjects
FG0150 subjects
FG0160 subjects
FG0170 subjects
FG0180 subjects
FG0190 subjects
FG0200 subjects
FG0210 subjects
FG0220 subjects
8 subjects
FG0058 subjects
FG0065 subjects
FG0074 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG0140 subjects
FG0150 subjects
FG0160 subjects
FG0170 subjects
FG0180 subjects
FG0190 subjects
FG0200 subjects
FG0210 subjects
FG0220 subjects
1 subjects
FG0040 subjects
FG0051 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG0140 subjects
FG0150 subjects
FG0160 subjects
FG0170 subjects
FG0180 subjects
FG0190 subjects
FG0200 subjects
FG0210 subjects
FG0220 subjects
Adverse Event
FG0001 subjects
FG0012 subjects
FG0021 subjects
FG0032 subjects
FG0041 subjects
FG0051 subjects
FG0061 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG0140 subjects
FG0150 subjects
FG0160 subjects
FG0170 subjects
FG0180 subjects
FG0190 subjects
FG0200 subjects
FG0210 subjects
FG0220 subjects
Withdrawal by Subject
FG0004 subjects
FG0013 subjects
FG0024 subjects
FG0036 subjects
FG0045 subjects
FG0056 subjects
FG0064 subjects
FG0074 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG0140 subjects
FG0150 subjects
FG0160 subjects
FG0170 subjects
FG0180 subjects
FG0190 subjects
FG0200 subjects
FG0210 subjects
FG0220 subjects
Lost to Follow-up
FG0000 subjects
FG0010 subjects
FG0022 subjects
FG0030 subjects
FG0041 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG0140 subjects
FG0150 subjects
FG0160 subjects
FG0170 subjects
FG0180 subjects
FG0190 subjects
FG0200 subjects
FG0210 subjects
FG0220 subjects
Death
FG0001 subjects
FG0010 subjects
FG0020 subjects
FG0031 subjects
FG0040 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG0140 subjects
FG0150 subjects
FG0160 subjects
FG0170 subjects
FG0180 subjects
FG0190 subjects
FG0200 subjects
FG0210 subjects
FG0220 subjects
Administrative Decision
FG0000 subjects
FG0010 subjects
FG0021 subjects
FG0030 subjects
FG0040 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG0140 subjects
FG0150 subjects
FG0160 subjects
FG0170 subjects
FG0180 subjects
FG0190 subjects
FG0200 subjects
FG0210 subjects
FG0220 subjects
Noncompliance
FG0000 subjects
FG0010 subjects
FG0021 subjects
FG0030 subjects
FG0040 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG0140 subjects
FG0150 subjects
FG0160 subjects
FG0170 subjects
FG0180 subjects
FG0190 subjects
FG0200 subjects
FG0210 subjects
FG0220 subjects
On-study But No Month 24 Visit
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0031 subjects
FG0040 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG0140 subjects
FG0150 subjects
FG0160 subjects
FG0170 subjects
FG0180 subjects
FG0190 subjects
FG0200 subjects
FG0210 subjects
FG0220 subjects
Other
FG0000 subjects
FG0011 subjects
FG0020 subjects
FG0031 subjects
FG0041 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG0140 subjects
FG0150 subjects
FG0160 subjects
FG0170 subjects
FG0180 subjects
FG0190 subjects
FG0200 subjects
FG0210 subjects
FG0220 subjects
0 subjects
FG0040 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG00818 subjects
FG00918 subjects
FG01020 subjects
FG01121 subjects
FG01293 subjects
FG01390 subjects
FG0140 subjects
FG0150 subjects
FG0160 subjects
FG0170 subjects
FG0180 subjects
FG0190 subjects
FG0200 subjects
FG0210 subjects
FG0220 subjects
Received Treatment
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG0040 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG00818 subjects
FG00918 subjectsIncludes one participant who received 1 dose of romosozumab 70 mg in error in first 12 months
FG01019 subjects
FG01119 subjects
FG01290 subjects
FG01388 subjects
FG0140 subjects
FG0150 subjects
FG0160 subjects
FG0170 subjects
FG0180 subjects
FG0190 subjects
FG0200 subjects
FG0210 subjects
FG0220 subjects
COMPLETED
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG0040 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG00817 subjects
FG00918 subjects
FG01018 subjects
FG01119 subjects
FG01288 subjects
FG01388 subjects
FG0140 subjects
FG0150 subjects
FG0160 subjects
FG0170 subjects
FG0180 subjects
FG0190 subjects
FG0200 subjects
FG0210 subjects
FG0220 subjects
NOT COMPLETED
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG0040 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0081 subjects
FG0090 subjects
FG0102 subjects
FG0112 subjects
FG0125 subjects
FG0132 subjects
FG0140 subjects
FG0150 subjects
FG0160 subjects
FG0170 subjects
FG0180 subjects
FG0190 subjects
FG0200 subjects
FG0210 subjects
FG0220 subjects
Type
Comment
Reasons
Protocol Deviation
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG0040 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0081 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG0140 subjects
FG0150 subjects
FG0160 subjects
FG0170 subjects
FG0180 subjects
FG0190 subjects
FG0200 subjects
FG0210 subjects
FG0220 subjects
Noncompliance
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Adverse Event
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Withdrawal by Subject
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Other
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
0 subjects
FG0040 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG01412 subjects
FG01516 subjects
FG01672 subjects
FG01767 subjects
FG0180 subjects
FG0190 subjects
FG0200 subjects
FG0210 subjects
FG0220 subjects
Received Romosozumab
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG0040 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG01412 subjects
FG01516 subjectsIncludes one participant who received 1 dose of romosozumab 70 mg in error in first 12 months
FG01672 subjects
FG01767 subjects
FG0180 subjects
FG0190 subjects
FG0200 subjects
FG0210 subjects
FG0220 subjects
COMPLETED
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG0040 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG01412 subjects
FG01514 subjects
FG01665 subjects
FG01764 subjects
FG0180 subjects
FG0190 subjects
FG0200 subjects
FG0210 subjects
FG0220 subjects
NOT COMPLETED
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG0040 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG0140 subjects
FG0152 subjects
FG0167 subjects
FG0173 subjects
FG0180 subjects
FG0190 subjects
FG0200 subjects
FG0210 subjects
FG0220 subjects
Type
Comment
Reasons
Adverse Event
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG0040 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG0140 subjects
FG0151 subjects
FG0163 subjects
FG0170 subjects
FG0180 subjects
FG0190 subjects
FG0200 subjects
FG0210 subjects
FG0220 subjects
Withdrawal by Subject
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Lost to Follow-up
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Other
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Continuing the re-treatment phase
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
0 subjects
FG0040 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG0140 subjects
FG0150 subjects
FG0160 subjects
FG0170 subjects
FG01851 subjects
FG01911 subjects
FG02012 subjects
FG02159 subjects
FG0228 subjects
Received Zoledronic Acid
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG0040 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG0140 subjects
FG0150 subjects
FG0160 subjects
FG0170 subjects
FG0180 subjects
FG01911 subjects
FG02012 subjects
FG02156 subjects
FG0228 subjects
COMPLETED
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG0040 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG0140 subjects
FG0150 subjects
FG0160 subjects
FG0170 subjects
FG01850 subjects
FG01911 subjects
FG02012 subjects
FG02157 subjects
FG0228 subjects
NOT COMPLETED
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG0040 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG0140 subjects
FG0150 subjects
FG0160 subjects
FG0170 subjects
FG0181 subjects
FG0190 subjects
FG0200 subjects
FG0212 subjects
FG0220 subjects
Type
Comment
Reasons
Death
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG0040 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG0140 subjects
FG0150 subjects
FG0160 subjects
FG0170 subjects
FG0181 subjects
FG0190 subjects
FG0200 subjects
FG0210 subjects
FG0220 subjects
Ineligibility Determined
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Withdrawal by Subject
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
BG002
Teriparatide
Participants received open-label teriparatide 20 μg subcutaneously every day (QD) for 12 months. At month 12 participants ended study participation.
BG003
Romosozumab 70 mg QM
Participants received double-blind romosozumab 70 mg subcutaneously every month for 24 months.
BG004
Romosozumab 140 mg Q3M
Participants received double-blind romosozumab 140 mg subcutaneously once every 3 months for 24 months.
BG005
Romosozumab 140 mg QM
Participants received double-blind romosozumab 140 mg QM subcutaneously for 24 months.
BG006
Romosozumab 210 mg Q3M
Participants received double-blind romosozumab 210 mg Q3M subcutaneously for 24 months.
BG007
Romosozumab 210 mg QM
Participants received double-blind romosozumab 210 mg QM subcutaneously for 24 months.
BG008
Total
Total of all reporting groups
52
BG00151
BG00255
BG00351
BG00454
BG00551
BG00653
BG00752
BG008419
Standard Deviation
years
Title
Denominators
Categories
ParticipantsBG00052
ParticipantsBG00151
ParticipantsBG00255
ParticipantsBG00351
ParticipantsBG00454
ParticipantsBG00551
ParticipantsBG00653
ParticipantsBG00752
ParticipantsBG008419
Title
Measurements
BG00067.0± 6.5
BG00167.1± 5.8
BG00266.8± 5.7
BG003
Age, Customized
Count of Participants
Participants
Title
Denominators
Categories
ParticipantsBG00052
ParticipantsBG00151
ParticipantsBG00255
ParticipantsBG00351
ParticipantsBG00454
ParticipantsBG00551
ParticipantsBG00653
ParticipantsBG00752
ParticipantsBG008419
Title
Measurements
< 65 years
BG00020
BG00118
BG00221
BG003
Sex: Female, Male
Count of Participants
Participants
Title
Denominators
Categories
ParticipantsBG00052
ParticipantsBG00151
ParticipantsBG00255
ParticipantsBG00351
ParticipantsBG00454
ParticipantsBG00551
ParticipantsBG00653
ParticipantsBG00752
ParticipantsBG008419
Title
Measurements
Female
BG00052
BG00151
BG00255
BG003
Race/Ethnicity, Customized
Count of Participants
Participants
Title
Denominators
Categories
ParticipantsBG00052
ParticipantsBG00151
ParticipantsBG00255
ParticipantsBG00351
ParticipantsBG00454
ParticipantsBG00551
ParticipantsBG00653
ParticipantsBG00752
ParticipantsBG008419
Title
Measurements
White or Caucasian
BG00047
BG00146
BG00244
BG003
Lumbar Spine Bone Mineral Density (BMD) T-score
The T-score is the bone mineral density (BMD) at the site when compared to that of a healthy thirty-year-old. A normal T-score is -1.0 or higher; Osteopenia is defined as between -1.0 and -2.5; Osteoporosis is defined as -2.5 or lower, meaning a bone density that is two and a half standard deviations below the mean of a thirty-year-old man/woman.
Mean
Standard Deviation
T-score
Title
Denominators
Categories
ParticipantsBG00052
ParticipantsBG00151
ParticipantsBG00255
ParticipantsBG00351
ParticipantsBG00454
ParticipantsBG00551
ParticipantsBG00653
ParticipantsBG00752
ParticipantsBG008419
Title
Measurements
BG000-2.29± 0.66
BG001-2.08± 0.69
BG002-2.29± 0.57
BG003
Total Hip BMD T-score
Mean
Standard Deviation
T-score
Title
Denominators
Categories
ParticipantsBG00052
ParticipantsBG00151
ParticipantsBG00255
ParticipantsBG00351
ParticipantsBG00454
ParticipantsBG00551
ParticipantsBG00653
ParticipantsBG00752
ParticipantsBG008419
Title
Measurements
BG000-1.35± 0.67
BG001-1.55± 0.68
BG002-1.32± 0.78
BG003
Femoral Neck BMD T-score
Mean
Standard Deviation
T-score
Title
Denominators
Categories
ParticipantsBG00052
ParticipantsBG00151
ParticipantsBG00255
ParticipantsBG00351
ParticipantsBG00454
ParticipantsBG00551
ParticipantsBG00653
ParticipantsBG00752
ParticipantsBG008419
Title
Measurements
BG000-1.76± 0.56
BG001-1.91± 0.61
BG002-1.79± 0.67
BG003
Distal 1/3 Radius BMD T-score
Participants with available data
Mean
Standard Deviation
T-score
Title
Denominators
Categories
ParticipantsBG00051
ParticipantsBG00150
ParticipantsBG00250
ParticipantsBG00349
ParticipantsBG00452
ParticipantsBG00547
ParticipantsBG00652
ParticipantsBG00749
ParticipantsBG008400
Title
Measurements
BG000-1.85± 1.04
BG001-2.08± 0.99
BG002-2.05± 1.21
BG003
Serum Type 1 Collagen C-telopeptide (CTX)
Participants with available data
Median
Inter-Quartile Range
ng/L
Title
Denominators
Categories
ParticipantsBG00051
ParticipantsBG00151
ParticipantsBG00254
ParticipantsBG00349
ParticipantsBG00453
ParticipantsBG00548
ParticipantsBG00653
ParticipantsBG00751
ParticipantsBG008410
Title
Measurements
BG000481.0(347.0 to 673.0)
BG001494.0(373.0 to 614.0)
BG002505.5(410.0 to 690.0)
BG003
Serum Procollagen Type 1 N-telopeptide (P1NP)
Participants with available data
Median
Inter-Quartile Range
μg/L
Title
Denominators
Categories
ParticipantsBG00051
ParticipantsBG00151
ParticipantsBG00254
ParticipantsBG00349
ParticipantsBG00453
ParticipantsBG00548
ParticipantsBG00653
ParticipantsBG00751
ParticipantsBG008410
Title
Measurements
BG00047.76(37.92 to 59.12)
BG00149.25(40.05 to 57.73)
BG00248.78(42.45 to 66.98)
BG003
Osteocalcin
Participants with available data
Median
Inter-Quartile Range
ng/mL
Title
Denominators
Categories
ParticipantsBG00051
ParticipantsBG00151
ParticipantsBG00254
ParticipantsBG00349
ParticipantsBG00453
ParticipantsBG00548
ParticipantsBG00653
ParticipantsBG00751
ParticipantsBG008410
Title
Measurements
BG00017.95(15.78 to 23.62)
BG00119.37(14.69 to 24.78)
BG00219.47(15.93 to 26.14)
BG003
Bone-specific Alkaline Phosphatase (BSAP)
Participants with available data
Median
Inter-Quartile Range
μg/L
Title
Denominators
Categories
ParticipantsBG00051
ParticipantsBG00151
ParticipantsBG00254
ParticipantsBG00349
ParticipantsBG00453
ParticipantsBG00548
ParticipantsBG00653
ParticipantsBG00751
ParticipantsBG008410
Title
Measurements
BG00011.79(9.75 to 13.53)
BG00112.93(10.48 to 15.52)
BG00213.34(10.04 to 16.39)
BG003
OG002
Teriparatide
Participants received open-label teriparatide 20 μg subcutaneously every day (QD) for 12 months. At month 12 participants ended study participation.
OG003
Romosozumab 70 mg QM
Participants received double-blind romosozumab 70 mg subcutaneously every month for 24 months.
OG004
Romosozumab 140 mg Q3M
Participants received double-blind romosozumab 140 mg subcutaneously once every 3 months for 24 months.
OG005
Romosozumab 140 mg QM
Participants received double-blind romosozumab 140 mg QM subcutaneously for 24 months.
OG006
Romosozumab 210 mg Q3M
Participants received double-blind romosozumab 210 mg Q3M subcutaneously for 24 months.
OG007
Romosozumab 210 mg QM
Participants received double-blind romosozumab 210 mg QM subcutaneously for 24 months.
OG008
Romosozumab Monthly
Participants who received once a month dosing of romosozumab (70, 140 or 210 mg).
OG009
Romosozumab Every 3 Months
Participants who received romosozumab every 3 months (140 or 210 mg)
OG010
Romosozumab 140 mg
Participants who received romosozumab 140 mg dosing (QM or Q3M).
OG011
Romosozumab 210 mg
Participants who received romosozumab 210 mg dosing (QM or Q3M).
Units
Counts
Participants
OG00047
OG00147
OG00246
OG00344
OG00449
OG00546
OG00651
OG00749
OG008139
OG009100
OG01095
OG011100
Title
Denominators
Categories
Title
Measurements
OG000-0.1(-1.2 to 0.9)
OG0014.1(3.0 to 5.1)
OG0027.1(6.1 to 8.2)
OG0035.4(4.3 to 6.4)
OG0045.4(4.4 to 6.5)
OG0059.1(8.0 to 10.2)
OG0065.5(4.4 to 6.6)
OG00711.3(10.3 to 12.4)
OG0088.6(7.9 to 9.3)
OG0095.5(4.7 to 6.3)
OG0107.3(6.4 to 8.1)
OG0118.4(7.6 to 9.2)
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG008
A linear mixed effects model was fit with the percent change from baseline to months 3, 6 and 12 in BMD of the lumbar spine as the dependent variable and baseline BMD, machine type, interaction of baseline BMD and machine type, geographic region (Latin America, North America, Europe), visit, treatment regimen (categorical), interaction of treatment regimen and visit as the independent variables.
Linear Mixed Effects Model
< 0.0001
P-value is adjusted by the Hochberg procedure for comparisons to placebo.
LS Mean Difference from Placebo
8.7
2-Sided
95
7.5
9.9
Superiority
OG000
OG009
A linear mixed effects model was fit with the percent change from baseline to months 3, 6 and 12 in BMD of the lumbar spine as the dependent variable and baseline BMD, machine type, interaction of baseline BMD and machine type, geographic region (Latin America, North America, Europe), visit, treatment regimen (categorical), interaction of treatment regimen and visit as the independent variables.
Linear Mixed Effects Model
< 0.0001
P-value is adjusted by the Hochberg procedure for comparisons to placebo.
LS Mean Difference from placebo
5.6
2-Sided
95
4.3
6.9
Superiority
OG000
OG010
A linear mixed effects model was fit with the percent change from baseline to months 3, 6 and 12 in BMD of the lumbar spine as the dependent variable and baseline BMD, machine type, interaction of baseline BMD and machine type, geographic region (Latin America, North America, Europe), visit, treatment regimen (categorical), interaction of treatment regimen and visit as the independent variables.
Linear Mixed Effects Model
< 0.0001
P-value is adjusted by the Hochberg procedure for comparisons to placebo.
LS Mean Difference from Placebo
7.4
2-Sided
95
6.1
8.7
Superiority
OG000
OG011
A linear mixed effects model was fit with the percent change from baseline to months 3, 6 and 12 in BMD of the lumbar spine as the dependent variable and baseline BMD, machine type, interaction of baseline BMD and machine type, geographic region (Latin America, North America, Europe), visit, treatment regimen (categorical), interaction of treatment regimen and visit as the independent variables.
Linear Mixed Effects Model
< 0.0001
P-value is adjusted by the Hochberg procedure for comparisons to placebo.
LS Mean Difference from Placebo
8.5
2-Sided
95
7.3
9.8
Superiority
Secondary
Percent Change From Baseline at Month 6 in BMD at the Lumbar Spine
Bone mineral density was measured using dual energy x-ray absorptiometry (DXA). Images were analyzed by a central imaging reader.
Percent change from baseline to month 6 was analyzed using a linear mixed effects model with the percent change from baseline to month 6 in DXA BMD as dependent variable, and baseline BMD value, machine type, geographic region, interaction of baseline BMD and machine type, visit, treatment (categorical) and interaction of treatment and visit as the independent variables.
All randomized participants who had non-missing baseline and month 6 measurements.
Posted
Least Squares Mean
95% Confidence Interval
percent change
Baseline to 6 months
ID
Title
Description
OG000
Placebo
Participants received placebo matching to romosozumab once a month (QM) or once every 3 months (Q3M) administered subcutaneously for 24 months.
OG001
Alendronate
Participants received open-label alendronate (ALN) 70 mg orally (PO) every week (QW) for 12 months. At month 12 participants transitioned to receive romosozumab 140 mg subcutaneously every month for an additional 12 months (months 12 to 24).
OG002
Teriparatide
Participants received open-label teriparatide 20 μg subcutaneously every day (QD) for 12 months. At month 12 participants ended study participation.
OG003
Romosozumab 70 mg QM
Participants received double-blind romosozumab 70 mg subcutaneously every month for 24 months.
OG004
Romosozumab 140 mg Q3M
Participants received double-blind romosozumab 140 mg subcutaneously once every 3 months for 24 months.
OG005
Romosozumab 140 mg QM
Participants received double-blind romosozumab 140 mg QM subcutaneously for 24 months.
OG006
Romosozumab 210 mg Q3M
Participants received double-blind romosozumab 210 mg Q3M subcutaneously for 24 months.
OG007
Romosozumab 210 mg QM
Participants received double-blind romosozumab 210 mg QM subcutaneously for 24 months.
Units
Counts
Participants
OG00049
OG00149
OG00248
OG003
Title
Denominators
Categories
Title
Measurements
OG0000.3(-0.7 to 1.3)
OG0012.6(1.6 to 3.6)
OG0024.8(3.8 to 5.8)
OG003
Secondary
Percent Change From Baseline at Month 6 in BMD of the Total Hip
Bone mineral density was measured using dual energy x-ray absorptiometry (DXA). Images were analyzed by a central imaging reader.
Percent change from baseline to month 6 was analyzed using a linear mixed effects model with the percent change from baseline to month 6 in DXA BMD as dependent variable, and baseline BMD value, machine type, geographic region, interaction of baseline BMD and machine type, visit, treatment (categorical) and interaction of treatment and visit as the independent variables.
All randomized participants who had non-missing baseline and month 6 measurements.
Posted
Least Squares Mean
95% Confidence Interval
percent change
Baseline to 6 months
ID
Title
Description
OG000
Placebo
Participants received placebo matching to romosozumab once a month (QM) or once every 3 months (Q3M) administered subcutaneously for 24 months.
OG001
Alendronate
Participants received open-label alendronate (ALN) 70 mg orally (PO) every week (QW) for 12 months. At month 12 participants transitioned to receive romosozumab 140 mg subcutaneously every month for an additional 12 months (months 12 to 24).
OG002
Teriparatide
Participants received open-label teriparatide 20 μg subcutaneously every day (QD) for 12 months. At month 12 participants ended study participation.
OG003
Romosozumab 70 mg QM
Participants received double-blind romosozumab 70 mg subcutaneously every month for 24 months.
OG004
Romosozumab 140 mg Q3M
Participants received double-blind romosozumab 140 mg subcutaneously once every 3 months for 24 months.
OG005
Romosozumab 140 mg QM
Participants received double-blind romosozumab 140 mg QM subcutaneously for 24 months.
OG006
Romosozumab 210 mg Q3M
Participants received double-blind romosozumab 210 mg Q3M subcutaneously for 24 months.
OG007
Romosozumab 210 mg QM
Participants received double-blind romosozumab 210 mg QM subcutaneously for 24 months.
Units
Counts
Participants
OG00049
OG00149
OG00248
OG003
Title
Denominators
Categories
Title
Measurements
OG000-0.6(-1.2 to -0.1)
OG0010.9(0.3 to 1.5)
OG0020.5(-0.0 to 1.1)
OG003
Secondary
Percent Change From Baseline at Month 6 in BMD of the Femoral Neck
Bone mineral density was measured using dual energy x-ray absorptiometry (DXA). Images were analyzed by a central imaging reader.
Percent change from baseline to month 6 was analyzed using a linear mixed effects model with the percent change from baseline to month 6 in DXA BMD as dependent variable, and baseline BMD value, machine type, geographic region, interaction of baseline BMD and machine type, visit, treatment (categorical) and interaction of treatment and visit as the independent variables.
All randomized participants who had non-missing baseline and month 6 measurements.
Posted
Least Squares Mean
95% Confidence Interval
percent change
Baseline to 6 months
ID
Title
Description
OG000
Placebo
Participants received placebo matching to romosozumab once a month (QM) or once every 3 months (Q3M) administered subcutaneously for 24 months.
OG001
Alendronate
Participants received open-label alendronate (ALN) 70 mg orally (PO) every week (QW) for 12 months. At month 12 participants transitioned to receive romosozumab 140 mg subcutaneously every month for an additional 12 months (months 12 to 24).
OG002
Teriparatide
Participants received open-label teriparatide 20 μg subcutaneously every day (QD) for 12 months. At month 12 participants ended study participation.
OG003
Romosozumab 70 mg QM
Participants received double-blind romosozumab 70 mg subcutaneously every month for 24 months.
OG004
Romosozumab 140 mg Q3M
Participants received double-blind romosozumab 140 mg subcutaneously once every 3 months for 24 months.
OG005
Romosozumab 140 mg QM
Participants received double-blind romosozumab 140 mg QM subcutaneously for 24 months.
OG006
Romosozumab 210 mg Q3M
Participants received double-blind romosozumab 210 mg Q3M subcutaneously for 24 months.
OG007
Romosozumab 210 mg QM
Participants received double-blind romosozumab 210 mg QM subcutaneously for 24 months.
Units
Counts
Participants
OG00049
OG00149
OG00248
OG003
Title
Denominators
Categories
Title
Measurements
OG000-0.4(-1.3 to 0.4)
OG0010.5(-0.3 to 1.4)
OG0020.5(-0.3 to 1.3)
OG003
Secondary
Percent Change From Baseline at Month 12 in BMD of the Total Hip
Bone mineral density was measured using dual energy x-ray absorptiometry (DXA). Images were analyzed by a central imaging reader.
Percent change from baseline to 12 months in BMD was analyzed using a linear mixed effects model with the percent change from baseline to month 12 in DXA BMD as dependent variable, and baseline BMD value, machine type, geographic region, interaction of baseline BMD and machine type, visit, treatment (categorical) and interaction of treatment and visit as the independent variables.
All randomized participants who had non-missing baseline and month 12 measurements.
Posted
Least Squares Mean
95% Confidence Interval
percent change
Baseline to 12 months
ID
Title
Description
OG000
Placebo
Participants received placebo matching to romosozumab once a month (QM) or once every 3 months (Q3M) administered subcutaneously for 24 months.
OG001
Alendronate
Participants received open-label alendronate (ALN) 70 mg orally (PO) every week (QW) for 12 months. At month 12 participants transitioned to receive romosozumab 140 mg subcutaneously every month for an additional 12 months (months 12 to 24).
OG002
Teriparatide
Participants received open-label teriparatide 20 μg subcutaneously every day (QD) for 12 months. At month 12 participants ended study participation.
OG003
Romosozumab 70 mg QM
Participants received double-blind romosozumab 70 mg subcutaneously every month for 24 months.
OG004
Romosozumab 140 mg Q3M
Participants received double-blind romosozumab 140 mg subcutaneously once every 3 months for 24 months.
OG005
Romosozumab 140 mg QM
Participants received double-blind romosozumab 140 mg QM subcutaneously for 24 months.
OG006
Romosozumab 210 mg Q3M
Participants received double-blind romosozumab 210 mg Q3M subcutaneously for 24 months.
OG007
Romosozumab 210 mg QM
Participants received double-blind romosozumab 210 mg QM subcutaneously for 24 months.
Units
Counts
Participants
OG00047
OG00147
OG00246
OG003
Title
Denominators
Categories
Title
Measurements
OG000-0.7(-1.4 to -0.1)
OG0011.9(1.3 to 2.6)
OG0021.3(0.7 to 2.0)
OG003
Secondary
Percent Change From Baseline at Month 12 in BMD of the Femoral Neck
Bone mineral density was measured using dual energy x-ray absorptiometry (DXA). Images were analyzed by a central imaging reader.
Percent change from baseline to 12 months in BMD was analyzed using a linear mixed effects model with the percent change from baseline to month 12 in DXA BMD as dependent variable, and baseline BMD value, machine type, geographic region, interaction of baseline BMD and machine type, visit, treatment (categorical) and interaction of treatment and visit as the independent variables.
All randomized participants who had non-missing baseline and month 12 measurements.
Posted
Least Squares Mean
95% Confidence Interval
percent change
Baseline to 12 months
ID
Title
Description
OG000
Placebo
Participants received placebo matching to romosozumab once a month (QM) or once every 3 months (Q3M) administered subcutaneously for 24 months.
OG001
Alendronate
Participants received open-label alendronate (ALN) 70 mg orally (PO) every week (QW) for 12 months. At month 12 participants transitioned to receive romosozumab 140 mg subcutaneously every month for an additional 12 months (months 12 to 24).
OG002
Teriparatide
Participants received open-label teriparatide 20 μg subcutaneously every day (QD) for 12 months. At month 12 participants ended study participation.
OG003
Romosozumab 70 mg QM
Participants received double-blind romosozumab 70 mg subcutaneously every month for 24 months.
OG004
Romosozumab 140 mg Q3M
Participants received double-blind romosozumab 140 mg subcutaneously once every 3 months for 24 months.
OG005
Romosozumab 140 mg QM
Participants received double-blind romosozumab 140 mg QM subcutaneously for 24 months.
OG006
Romosozumab 210 mg Q3M
Participants received double-blind romosozumab 210 mg Q3M subcutaneously for 24 months.
OG007
Romosozumab 210 mg QM
Participants received double-blind romosozumab 210 mg QM subcutaneously for 24 months.
Units
Counts
Participants
OG00047
OG00147
OG00246
OG003
Title
Denominators
Categories
Title
Measurements
OG000-1.1(-2.0 to -0.2)
OG0011.2(0.3 to 2.1)
OG0021.1(0.2 to 2.0)
OG003
Secondary
Percent Change From Baseline at Month 12 in BMD of the Distal Radius
Bone mineral density was measured using dual energy x-ray absorptiometry (DXA). Images were analyzed by a central imaging reader.
Percent change from baseline in distal radius BMD was analyzed using an analysis of covariance (ANCOVA) model with the percent change from baseline to Month 12 in DXA BMD as dependent variable, baseline BMD value, machine type, interaction of baseline BMD and machine type, treatment (categorical) and geographic region as the independent class variables.
All randomized participants who had non-missing baseline and month 12 measurements.
Posted
Least Squares Mean
95% Confidence Interval
percent change
Baseline to 12 months
ID
Title
Description
OG000
Placebo
Participants received placebo matching to romosozumab once a month (QM) or once every 3 months (Q3M) administered subcutaneously for 24 months.
OG001
Alendronate
Participants received open-label alendronate (ALN) 70 mg orally (PO) every week (QW) for 12 months. At month 12 participants transitioned to receive romosozumab 140 mg subcutaneously every month for an additional 12 months (months 12 to 24).
OG002
Teriparatide
Participants received open-label teriparatide 20 μg subcutaneously every day (QD) for 12 months. At month 12 participants ended study participation.
OG003
Romosozumab 70 mg QM
Participants received double-blind romosozumab 70 mg subcutaneously every month for 24 months.
OG004
Romosozumab 140 mg Q3M
Participants received double-blind romosozumab 140 mg subcutaneously once every 3 months for 24 months.
OG005
Romosozumab 140 mg QM
Participants received double-blind romosozumab 140 mg QM subcutaneously for 24 months.
OG006
Romosozumab 210 mg Q3M
Participants received double-blind romosozumab 210 mg Q3M subcutaneously for 24 months.
OG007
Romosozumab 210 mg QM
Participants received double-blind romosozumab 210 mg QM subcutaneously for 24 months.
Units
Counts
Participants
OG00048
OG00146
OG00242
OG003
Title
Denominators
Categories
Title
Measurements
OG000-0.9(-1.8 to 0.1)
OG001-0.3(-1.2 to 0.7)
OG002-1.7(-2.7 to -0.7)
OG003
Secondary
Percent Change From Baseline in Procollagen Type 1 N-telopeptide (P1NP)
Percent change from baseline in the bone turnover marker (BTM) P1NP was analyzed using a linear mixed effects model with the natural logarithm of the ratio of BTM (follow-up versus baseline) as the dependent variables, and visit, treatment (categorical), interaction of treatment and visit and the natural logarithm of the baseline BTM as the independent variables; outcomes were then transformed back to percent change from baseline.
All randomized participants with baseline and at least one post baseline measurement on or prior to the month 12 visit and with available data at each time point. Data were not collected for participants in the alendronate and teriparatide groups at month 1.
Posted
Least Squares Mean
95% Confidence Interval
percent change
Baseline and months 1, 3, 6, 9, and 12
ID
Title
Description
OG000
Placebo
Participants received placebo matching to romosozumab once a month (QM) or once every 3 months (Q3M) administered subcutaneously for 24 months.
OG001
Alendronate
Participants received open-label alendronate (ALN) 70 mg orally (PO) every week (QW) for 12 months. At month 12 participants transitioned to receive romosozumab 140 mg subcutaneously every month for an additional 12 months (months 12 to 24).
OG002
Teriparatide
Participants received open-label teriparatide 20 μg subcutaneously every day (QD) for 12 months. At month 12 participants ended study participation.
OG003
Romosozumab 70 mg QM
Participants received double-blind romosozumab 70 mg subcutaneously every month for 24 months.
OG004
Romosozumab 140 mg Q3M
Participants received double-blind romosozumab 140 mg subcutaneously once every 3 months for 24 months.
OG005
Romosozumab 140 mg QM
Participants received double-blind romosozumab 140 mg QM subcutaneously for 24 months.
OG006
Romosozumab 210 mg Q3M
Participants received double-blind romosozumab 210 mg Q3M subcutaneously for 24 months.
OG007
Romosozumab 210 mg QM
Participants received double-blind romosozumab 210 mg QM subcutaneously for 24 months.
Units
Counts
Participants
OG00050
OG00151
OG00249
OG003
Title
Denominators
Categories
Month 1
ParticipantsOG00050
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG003
Secondary
Percent Change From Baseline in Type 1 Collagen C-telopeptide (CTX)
Percent change from baseline in the bone turnover marker (BTM) CTX was analyzed using a linear mixed effects model with the natural logarithm of the ratio of BTM (follow-up versus baseline) as the dependent variables, and visit, treatment (categorical), interaction of treatment and visit and the natural logarithm of the baseline BTM as the independent variables; outcomes were then transformed back to percent change from baseline.
All randomized participants with baseline and at least one post baseline measurement on or prior to the month 12 visit and with available data at each time point. Data were not collected for participants in the alendronate and teriparatide groups at month 1.
Posted
Least Squares Mean
95% Confidence Interval
percent change
Baseline and months 1, 3, 6, 9, and 12
ID
Title
Description
OG000
Placebo
Participants received placebo matching to romosozumab once a month (QM) or once every 3 months (Q3M) administered subcutaneously for 24 months.
OG001
Alendronate
Participants received open-label alendronate (ALN) 70 mg orally (PO) every week (QW) for 12 months. At month 12 participants transitioned to receive romosozumab 140 mg subcutaneously every month for an additional 12 months (months 12 to 24).
OG002
Teriparatide
Participants received open-label teriparatide 20 μg subcutaneously every day (QD) for 12 months. At month 12 participants ended study participation.
OG003
Romosozumab 70 mg QM
Participants received double-blind romosozumab 70 mg subcutaneously every month for 24 months.
OG004
Romosozumab 140 mg Q3M
Participants received double-blind romosozumab 140 mg subcutaneously once every 3 months for 24 months.
OG005
Romosozumab 140 mg QM
Participants received double-blind romosozumab 140 mg QM subcutaneously for 24 months.
OG006
Romosozumab 210 mg Q3M
Participants received double-blind romosozumab 210 mg Q3M subcutaneously for 24 months.
OG007
Romosozumab 210 mg QM
Participants received double-blind romosozumab 210 mg QM subcutaneously for 24 months.
Units
Counts
Participants
OG00050
OG00151
OG00249
OG003
Title
Denominators
Categories
Month 1
ParticipantsOG00050
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG003
Secondary
Percent Change From Baseline in Osteocalcin
Percent change from baseline in the bone turnover marker (BTM) osteocalcin was analyzed using a linear mixed effects model with the natural logarithm of the ratio of BTM (follow-up versus baseline) as the dependent variables, and visit, treatment (categorical), interaction of treatment and visit and the natural logarithm of the baseline BTM as the independent variables; outcomes were then transformed back to percent change from baseline.
All randomized participants with baseline and at least one post baseline measurement on or prior to the month 12 visit and with available data at each time point. Data were not collected for participants in the alendronate and teriparatide groups at month 1.
Posted
Least Squares Mean
95% Confidence Interval
percent change
Baseline and months 1, 3, 6, 9, and 12
ID
Title
Description
OG000
Placebo
Participants received placebo matching to romosozumab once a month (QM) or once every 3 months (Q3M) administered subcutaneously for 24 months.
OG001
Alendronate
Participants received open-label alendronate (ALN) 70 mg orally (PO) every week (QW) for 12 months. At month 12 participants transitioned to receive romosozumab 140 mg subcutaneously every month for an additional 12 months (months 12 to 24).
OG002
Teriparatide
Participants received open-label teriparatide 20 μg subcutaneously every day (QD) for 12 months. At month 12 participants ended study participation.
OG003
Romosozumab 70 mg QM
Participants received double-blind romosozumab 70 mg subcutaneously every month for 24 months.
OG004
Romosozumab 140 mg Q3M
Participants received double-blind romosozumab 140 mg subcutaneously once every 3 months for 24 months.
OG005
Romosozumab 140 mg QM
Participants received double-blind romosozumab 140 mg QM subcutaneously for 24 months.
OG006
Romosozumab 210 mg Q3M
Participants received double-blind romosozumab 210 mg Q3M subcutaneously for 24 months.
OG007
Romosozumab 210 mg QM
Participants received double-blind romosozumab 210 mg QM subcutaneously for 24 months.
Units
Counts
Participants
OG00050
OG00151
OG00249
OG003
Title
Denominators
Categories
Month 1
ParticipantsOG00050
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG003
Secondary
Percent Change From Baseline in Bone-specific Alkaline Phosphatase (BSAP)
Percent change from baseline in the bone turnover marker (BTM) BSAP was analyzed using a linear mixed effects model with the natural logarithm of the ratio of BTM (follow-up versus baseline) as the dependent variables, and visit, treatment (categorical), interaction of treatment and visit and the natural logarithm of the baseline BTM as the independent variables; outcomes were then transformed back to percent change from baseline.
All randomized participants with baseline and at least one post baseline measurement on or prior to the month 12 visit and with available data at each time point. Data were not collected for participants in the alendronate and teriparatide groups at month 1.
Posted
Least Squares Mean
95% Confidence Interval
percent change
Baseline and months 1, 3, 6, 9, and 12
ID
Title
Description
OG000
Placebo
Participants received placebo matching to romosozumab once a month (QM) or once every 3 months (Q3M) administered subcutaneously for 24 months.
OG001
Alendronate
Participants received open-label alendronate (ALN) 70 mg orally (PO) every week (QW) for 12 months. At month 12 participants transitioned to receive romosozumab 140 mg subcutaneously every month for an additional 12 months (months 12 to 24).
OG002
Teriparatide
Participants received open-label teriparatide 20 μg subcutaneously every day (QD) for 12 months. At month 12 participants ended study participation.
OG003
Romosozumab 70 mg QM
Participants received double-blind romosozumab 70 mg subcutaneously every month for 24 months.
OG004
Romosozumab 140 mg Q3M
Participants received double-blind romosozumab 140 mg subcutaneously once every 3 months for 24 months.
OG005
Romosozumab 140 mg QM
Participants received double-blind romosozumab 140 mg QM subcutaneously for 24 months.
OG006
Romosozumab 210 mg Q3M
Participants received double-blind romosozumab 210 mg Q3M subcutaneously for 24 months.
OG007
Romosozumab 210 mg QM
Participants received double-blind romosozumab 210 mg QM subcutaneously for 24 months.
Units
Counts
Participants
OG00050
OG00151
OG00249
OG003
Title
Denominators
Categories
Month 1
ParticipantsOG00050
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG003
3
30
25
30
EG001
BL-Month 12: Placebo Q3M
Participants received placebo matching to romosozumab once every 3 months (Q3M) administered subcutaneously for 12 months.
4
20
19
20
EG002
BL-Month 12: Alendronate
Participants received open-label alendronate (ALN) 70 mg orally (PO) every week (QW) for 12 months.
4
51
38
51
EG003
BL-Month12: Teriparatide
Participants received open-label teriparatide 20 μg subcutaneously every day (QD) for 12 months.
5
54
36
54
EG004
BL-Month 12: Romosozumab 70 mg QM
Participants received double-blind romosozumab 70 mg subcutaneously every month for 12 months.
5
50
46
50
EG005
BL-Month 12: Romosozumab 140 mg Q3M
Participants received double-blind romosozumab 140 mg subcutaneously once every 3 months for 12 months.
3
52
40
52
EG006
BL-Month 12: Romosozumab 140 mg QM
Participants received double-blind romosozumab 140 mg subcutaneously every month for 12 months.
2
49
41
49
EG007
BL-Month 12: Romosozumab 210 mg Q3M
Participants received double-blind romosozumab 210 mg Q3M subcutaneously for 12 months.
3
53
45
53
EG008
BL-Month 12: Romosozumab 210 mg QM
Participants received double-blind romosozumab 210 mg QM subcutaneously for 12 months.
6
51
40
51
EG009
BL-Month 24: Placebo QM
Participants received placebo matching to romosozumab QM administered subcutaneously for 24 months.
5
30
28
30
EG010
BL-Month 24: Placebo Q3M
Participants received placebo matching to romosozumab Q3M administered subcutaneously for 24 months.
4
20
20
20
EG011
BL-Month 24: ALN/Romosozumab 140 mg QM
Participants received open-label alendronate (ALN) 70 mg PO QW for 12 months. At month 12 participants transitioned to receive romosozumab 140 mg subcutaneously every month for an additional 12 months (months 12 to 24).
8
51
49
51
EG012
BL-Month 24: Romosozumab 70 mg QM
Participants received double-blind romosozumab 70 mg subcutaneously every month for 24 months.
9
50
48
50
EG013
BL-Month 24: Romosozumab 140 mg Q3M
Participants received double-blind romosozumab 140 mg subcutaneously once every 3 months for 24 months.
8
52
47
52
EG014
BL-Month 24: Romosozumab 140 mg QM
Participants received double-blind romosozumab 140 mg subcutaneously every month for 24 months.
8
49
46
49
EG015
BL-Month 24: Romosozumab 210 mg Q3M
Participants received double-blind romosozumab 210 mg Q3M subcutaneously for 24 months.
6
53
51
53
EG016
BL-Month 24: Romosozumab 210 mg QM
Participants received double-blind romosozumab 210 mg QM subcutaneously for 24 months.
7
51
47
51
EG017
Month 24-36: Placebo/Placebo
Participants who received placebo in the 24-month romosozumab treatment phase then received placebo to denosumab subcutaneously once every 6 months for 12 months during the denosumab extension phase.
2
18
15
18
EG018
Month 24-36: Placebo/Denosumab
Participants who received placebo in the 24-month romosozumab treatment phase then received denosumab 60 mg subcutaneously once every 6 months for 12 months during the denosumab extension phase.
1
17
15
17
EG019
Month 24-36: ALN/Romosozumab/Placebo
Participants who received alendronate for the first 12 months and romosozumab 140 mg subcutaneously every month from months 12 to 24 received placebo to denosumab subcutaneously once every 6 months for 12 months during the denosumab extension phase.
2
19
12
19
EG020
Month 24-36: ALN/Romosozumab/Denosumab
Participants who received alendronate for the first 12 months, romosozumab 140 mg subcutaneously every month from months 12-24 received denosumab 60 mg subcutaneously once every 6 months for 12 months during the denosumab extension phase.
0
19
15
19
EG021
Month 24-36: Romosozumab/Placebo
Participants who received romosozumab at any dose for 24 months in the romosozumab treatment phase received placebo to denosumab subcutaneously once every 6 months for 12 months during the denosumab extension phase.
3
90
57
90
EG022
Month 24-36: Romosozumab/Denosumab
Participants who received romosozumab at any dose for 24 months in the romosozumab treatment phase received denosumab 60 mg subcutaneously once every 6 months for 12 months during the denosumab extension phase.
8
89
59
89
EG023
Month 36-48: Placebo/Placebo/Romosozumab
Participants who received placebo in the first 24-month romosozumab treatment phase and placebo to denosumab during months 24 to 36 then received romosozumab 210 mg subcutaneously QM in the 12-month romosozumab retreatment phase (months 36 to 48).
0
12
12
12
EG024
Month 36-48: Placebo/Denosumab/Romosozumab
Participants who received placebo in the first 24-month romosozumab treatment phase and denosumab 60 mg during months 24 to 36 then received romosozumab 210 mg subcutaneously QM in the 12-month romosozumab retreatment phase (months 36 to 48).
1
15
11
15
EG025
Month 36-48: Romosozumab/Placebo/Romosozumab
Participants who received romosozumab at any dose during the first 24-month romosozumab treatment phase and placebo to denosumab during months 24 to 36 then received romosozumab 210 mg subcutaneously QM in the 12-month romosozumab retreatment phase (months 36 to 48).
4
72
53
72
EG026
Month 36-48: Romosozumab/Denosumab/Romosozumab
Participants who received romosozumab at any dose during the first 24-month romosozumab treatment phase and denosumab 60 mg during months 24 to 36 then received romosozumab 210 mg subcutaneously QM in the 12-month romosozumab retreatment phase (months 36 to 48).
Participants who received romosozumab at any dose during the first 24 month treatment phase, denosumab 60 mg during months 24 to 36 and romosozumab 210 mg QM in months 36 to 48 then received no intervention during the 24-month follow-on phase (months 48-72).
8
51
34
51
EG028
Month 48-72: Romosozumab/Placebo/Romosozumab/No
Participants who received romosozumab at any dose during the first 24 month treatment phase, placebo to denosumab during months 24 to 36 and romosozumab 210 mg QM in months 36 to 48 were assigned to the zoledronic acid treatment group, but received no intervention during the 24-month follow-on phase (months 48 to 72).
Participants who received placebo in the 24-month romosozumab treatment phase, placebo to denosumab during months 24 to 36 and romosozumab 210 mg QM in months 36 to 48 then received a single dose of open-label zoledronic acid 5 mg intravenously at month 48.
Participants who received placebo in the 24-month romosozumab treatment phase, denosumab 60 mg Q6M from months 24 to 36 and romosozumab 210 mg QM from months 36 to 48 then received a single dose of open-label zoledronic acid 5 mg intravenously at month 48.
Participants who received romosozumab at any dose during the 24-month romosozumab treatment phase, placebo to denosumab during months 24 to 36 and romosozumab 210 mg QM in months 36 to 48 then received a single dose of open-label zoledronic acid 5 mg intravenously at month 48.
Participants who received romosozumab at any dose during the 24-month romosozumab treatment phase, denosumab 60 mg Q6M during months 24 to 36 and romosozumab 210 mg QM in months 36 to 48 then received a single dose of open-label zoledronic acid 5 mg intravenously at month 48.
1
8
7
8
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Acute myocardial infarction
Cardiac disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Angina pectoris
Cardiac disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Angina unstable
Cardiac disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Atrial fibrillation
Cardiac disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0131 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Atrioventricular block second degree
Cardiac disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Cardiac failure congestive
Cardiac disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Cardiac tamponade
Cardiac disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Cardio-respiratory arrest
Cardiac disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Coronary artery disease
Cardiac disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0031 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Mitral valve stenosis
Cardiac disorders
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Myocardial infarction
Cardiac disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Sinus node dysfunction
Cardiac disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0061 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Sinus tachycardia
Cardiac disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Hyperparathyroidism
Endocrine disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Iridocyclitis
Eye disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0301 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Abdominal pain upper
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Barrett's oesophagus
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0031 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Colitis ischaemic
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0131 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Diverticulum
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Gastric ulcer
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Gastrointestinal fistula
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Gastrointestinal necrosis
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0051 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0131 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Inguinal hernia
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0261 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Intestinal obstruction
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Irritable bowel syndrome
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Large intestine polyp
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0131 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Nausea
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0131 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Peritoneal haemorrhage
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Small intestinal obstruction
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Vomiting
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0131 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Asthenia
General disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Non-cardiac chest pain
General disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0081 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0191 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Bile duct stone
Hepatobiliary disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0081 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Cholangitis
Hepatobiliary disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Cholecystitis
Hepatobiliary disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Cholelithiasis
Hepatobiliary disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Anaphylactic reaction
Immune system disorders
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Abscess intestinal
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Appendicitis
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0131 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Appendicitis perforated
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Bronchitis
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0031 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Clostridium difficile colitis
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Diverticulitis
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0181 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Escherichia sepsis
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Gastroenteritis
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Lung infection
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0031 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Mycobacterium kansasii infection
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Pneumonia
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0051 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0131 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0313 affected56 at risk
EG0320 affected8 at risk
Pneumonia legionella
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Salpingitis
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0031 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Epicondylitis
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Fall
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0191 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Fibula fracture
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Head injury
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Postoperative ileus
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Radius fracture
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0081 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0321 affected8 at risk
Tibia fracture
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Ulna fracture
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0081 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Central obesity
Metabolism and nutrition disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Dehydration
Metabolism and nutrition disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Diabetes mellitus
Metabolism and nutrition disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Hyponatraemia
Metabolism and nutrition disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Ketoacidosis
Metabolism and nutrition disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0171 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Arthralgia
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Chondropathy
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Flank pain
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0131 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Foot deformity
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Intervertebral disc protrusion
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Musculoskeletal pain
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Osteoarthritis
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0131 affected52 at risk
EG0141 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0191 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0272 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Rotator cuff syndrome
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Acute lymphocytic leukaemia
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Anal cancer
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Breast cancer
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0081 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Colon adenoma
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Colon cancer
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0171 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Invasive ductal breast carcinoma
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0261 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Leiomyoma
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Lung neoplasm malignant
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0261 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Non-Hodgkin's lymphoma
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Renal neoplasm
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Renal oncocytoma
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0081 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Squamous cell carcinoma of lung
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Thyroid cancer
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0241 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Uterine cancer
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Amnesia
Nervous system disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Cerebral haemorrhage
Nervous system disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Cerebral ischaemia
Nervous system disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Cerebrovascular accident
Nervous system disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Coma
Nervous system disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Dementia Alzheimer's type
Nervous system disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Lacunar infarction
Nervous system disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Loss of consciousness
Nervous system disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Nerve compression
Nervous system disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Paraesthesia
Nervous system disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0061 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Transient ischaemic attack
Nervous system disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0031 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Tremor
Nervous system disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0061 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Depression
Psychiatric disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Haematuria
Renal and urinary disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0031 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Nephrolithiasis
Renal and urinary disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0131 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Stress urinary incontinence
Renal and urinary disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Hysterocele
Reproductive system and breast disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Ovarian cyst
Reproductive system and breast disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Rectocele
Reproductive system and breast disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Uterine polyp
Reproductive system and breast disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Uterine prolapse
Reproductive system and breast disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Vaginal prolapse
Reproductive system and breast disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Chronic obstructive pulmonary disease
Respiratory, thoracic and mediastinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0081 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Dyspnoea
Respiratory, thoracic and mediastinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0051 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0131 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Pleural effusion
Respiratory, thoracic and mediastinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Pulmonary embolism
Respiratory, thoracic and mediastinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Respiratory distress
Respiratory, thoracic and mediastinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Arteriosclerosis
Vascular disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Femoral artery occlusion
Vascular disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Hypertension
Vascular disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Angina pectoris
Cardiac disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0241 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Palpitations
Cardiac disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0031 affected54 at risk
EG0040 affected50 at risk
EG0051 affected52 at risk
EG0062 affected49 at risk
EG0071 affected53 at risk
EG0081 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0131 affected52 at risk
EG0143 affected49 at risk
EG0151 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0231 affected12 at risk
EG0240 affected15 at risk
EG0252 affected72 at risk
EG0261 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Ventricular extrasystoles
Cardiac disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0021 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0061 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Deafness neurosensory
Ear and labyrinth disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0191 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Presbyacusis
Ear and labyrinth disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0201 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Tinnitus
Ear and labyrinth disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0031 affected54 at risk
EG0040 affected50 at risk
EG0051 affected52 at risk
EG0061 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0131 affected52 at risk
EG0141 affected49 at risk
EG0152 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0181 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Vertigo
Ear and labyrinth disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0052 affected52 at risk
EG0061 affected49 at risk
EG0073 affected53 at risk
EG0082 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0133 affected52 at risk
EG0142 affected49 at risk
EG0153 affected53 at risk
EG0165 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0191 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0321 affected8 at risk
Vertigo positional
Ear and labyrinth disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0051 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0131 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0241 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Goitre
Endocrine disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0031 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0181 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Age-related macular degeneration
Eye disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Cataract
Eye disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0032 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0075 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0112 affected51 at risk
EG0122 affected50 at risk
EG0131 affected52 at risk
EG0142 affected49 at risk
EG0155 affected53 at risk
EG0160 affected51 at risk
EG0171 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0213 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0241 affected15 at risk
EG0251 affected72 at risk
EG0261 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0300 affected12 at risk
EG0312 affected56 at risk
EG0320 affected8 at risk
Dacryostenosis acquired
Eye disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0052 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0132 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0301 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Dry eye
Eye disorders
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0072 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0152 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Vision blurred
Eye disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Visual acuity reduced
Eye disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0301 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Vitreous floaters
Eye disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0042 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0123 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Abdominal discomfort
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0051 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0131 affected52 at risk
EG0141 affected49 at risk
EG0151 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0262 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Abdominal distension
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0031 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0082 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0162 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Abdominal pain
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0030 affected54 at risk
EG0043 affected50 at risk
EG0051 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0082 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0113 affected51 at risk
EG0124 affected50 at risk
EG0132 affected52 at risk
EG0141 affected49 at risk
EG0152 affected53 at risk
EG0164 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0312 affected56 at risk
EG0320 affected8 at risk
Abdominal pain upper
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0011 affected20 at risk
EG0022 affected51 at risk
EG0030 affected54 at risk
EG0044 affected50 at risk
EG0050 affected52 at risk
EG0061 affected49 at risk
EG0071 affected53 at risk
EG0081 affected51 at risk
EG0091 affected30 at risk
EG0101 affected20 at risk
EG0114 affected51 at risk
EG0124 affected50 at risk
EG0130 affected52 at risk
EG0143 affected49 at risk
EG0153 affected53 at risk
EG0163 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0253 affected72 at risk
EG0261 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Constipation
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0003 affected30 at risk
EG0010 affected20 at risk
EG0023 affected51 at risk
EG0032 affected54 at risk
EG0045 affected50 at risk
EG0052 affected52 at risk
EG0065 affected49 at risk
EG0075 affected53 at risk
EG0082 affected51 at risk
EG0093 affected30 at risk
EG0100 affected20 at risk
EG0114 affected51 at risk
EG0126 affected50 at risk
EG0133 affected52 at risk
EG0145 affected49 at risk
EG0155 affected53 at risk
EG0162 affected51 at risk
EG0171 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0212 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0261 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0312 affected56 at risk
EG0320 affected8 at risk
Diaphragmatic hernia
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Diarrhoea
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0002 affected30 at risk
EG0012 affected20 at risk
EG0022 affected51 at risk
EG0031 affected54 at risk
EG0043 affected50 at risk
EG0052 affected52 at risk
EG0064 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0093 affected30 at risk
EG0102 affected20 at risk
EG0113 affected51 at risk
EG0125 affected50 at risk
EG0133 affected52 at risk
EG0144 affected49 at risk
EG0152 affected53 at risk
EG0160 affected51 at risk
EG0171 affected18 at risk
EG0181 affected17 at risk
EG0191 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0232 affected12 at risk
EG0240 affected15 at risk
EG0252 affected72 at risk
EG0265 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0313 affected56 at risk
EG0320 affected8 at risk
Diverticulum
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0061 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0092 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0312 affected56 at risk
EG0320 affected8 at risk
Diverticulum intestinal
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0113 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0162 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Dry mouth
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0081 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0162 affected51 at risk
EG0170 affected18 at risk
EG0181 affected17 at risk
EG0190 affected19 at risk
EG0201 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Dyspepsia
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0002 affected30 at risk
EG0011 affected20 at risk
EG0022 affected51 at risk
EG0033 affected54 at risk
EG0044 affected50 at risk
EG0050 affected52 at risk
EG0061 affected49 at risk
EG0073 affected53 at risk
EG0080 affected51 at risk
EG0092 affected30 at risk
EG0101 affected20 at risk
EG0113 affected51 at risk
EG0126 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0155 affected53 at risk
EG0163 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0201 affected19 at risk
EG0211 affected90 at risk
EG0221 affected89 at risk
EG0231 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0261 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0300 affected12 at risk
EG0312 affected56 at risk
EG0320 affected8 at risk
Gastritis
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0012 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0052 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0081 affected51 at risk
EG0090 affected30 at risk
EG0102 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0134 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0261 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0321 affected8 at risk
Gastrooesophageal reflux disease
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0012 affected20 at risk
EG0021 affected51 at risk
EG0032 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0102 affected20 at risk
EG0111 affected51 at risk
EG0121 affected50 at risk
EG0131 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0261 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0312 affected56 at risk
EG0321 affected8 at risk
Haematochezia
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0171 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Haemorrhoids
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0031 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0081 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0122 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0162 affected51 at risk
EG0171 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0261 affected68 at risk
EG0273 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Haemorrhoids thrombosed
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0191 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Large intestine polyp
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0201 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Nausea
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0002 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0035 affected54 at risk
EG0049 affected50 at risk
EG0051 affected52 at risk
EG0063 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0093 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0129 affected50 at risk
EG0131 affected52 at risk
EG0144 affected49 at risk
EG0150 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0181 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0252 affected72 at risk
EG0263 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0300 affected12 at risk
EG0313 affected56 at risk
EG0320 affected8 at risk
Paraesthesia oral
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0191 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Toothache
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0061 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0093 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0151 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0252 affected72 at risk
EG0262 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0321 affected8 at risk
Vomiting
Gastrointestinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0030 affected54 at risk
EG0045 affected50 at risk
EG0051 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0082 affected51 at risk
EG0091 affected30 at risk
EG0101 affected20 at risk
EG0112 affected51 at risk
EG0126 affected50 at risk
EG0131 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0162 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0252 affected72 at risk
EG0263 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Asthenia
General disorders
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0031 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0301 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Discomfort
General disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0031 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Facial pain
General disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0201 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0261 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Fatigue
General disorders
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0044 affected50 at risk
EG0051 affected52 at risk
EG0065 affected49 at risk
EG0071 affected53 at risk
EG0082 affected51 at risk
EG0091 affected30 at risk
EG0101 affected20 at risk
EG0116 affected51 at risk
EG0126 affected50 at risk
EG0131 affected52 at risk
EG0147 affected49 at risk
EG0151 affected53 at risk
EG0162 affected51 at risk
EG0170 affected18 at risk
EG0181 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0261 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0313 affected56 at risk
EG0320 affected8 at risk
Gait disturbance
General disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0231 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Influenza like illness
General disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0052 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0082 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0122 affected50 at risk
EG0132 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0163 affected51 at risk
EG0171 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0241 affected15 at risk
EG0250 affected72 at risk
EG0261 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0293 affected11 at risk
EG0302 affected12 at risk
EG0319 affected56 at risk
EG0320 affected8 at risk
Injection site bruising
General disorders
MedDRA 18.1
Systematic Assessment
EG0002 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0031 affected54 at risk
EG0043 affected50 at risk
EG0051 affected52 at risk
EG0063 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0092 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0123 affected50 at risk
EG0131 affected52 at risk
EG0144 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Injection site erythema
General disorders
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0042 affected50 at risk
EG0051 affected52 at risk
EG0062 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0122 affected50 at risk
EG0131 affected52 at risk
EG0142 affected49 at risk
EG0152 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0241 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Injection site haematoma
General disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0051 affected52 at risk
EG0061 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0121 affected50 at risk
EG0131 affected52 at risk
EG0141 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0201 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Injection site pain
General disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0043 affected50 at risk
EG0052 affected52 at risk
EG0064 affected49 at risk
EG0074 affected53 at risk
EG0083 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0112 affected51 at risk
EG0124 affected50 at risk
EG0133 affected52 at risk
EG0145 affected49 at risk
EG0155 affected53 at risk
EG0163 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0242 affected15 at risk
EG0252 affected72 at risk
EG0263 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Injection site pruritus
General disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0241 affected15 at risk
EG0251 affected72 at risk
EG0262 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Injection site reaction
General disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0061 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0241 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Injection site urticaria
General disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0241 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Malaise
General disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0061 affected49 at risk
EG0070 affected53 at risk
EG0081 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0131 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0161 affected51 at risk
EG0171 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Oedema peripheral
General disorders
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0062 affected49 at risk
EG0072 affected53 at risk
EG0080 affected51 at risk
EG0092 affected30 at risk
EG0100 affected20 at risk
EG0113 affected51 at risk
EG0123 affected50 at risk
EG0130 affected52 at risk
EG0142 affected49 at risk
EG0152 affected53 at risk
EG0160 affected51 at risk
EG0172 affected18 at risk
EG0181 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0231 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0261 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Pain
General disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0031 affected54 at risk
EG0042 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0082 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0122 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0162 affected51 at risk
EG0170 affected18 at risk
EG0181 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0261 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0312 affected56 at risk
EG0320 affected8 at risk
Peripheral swelling
General disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0061 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0142 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0191 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0222 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Pyrexia
General disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0031 affected54 at risk
EG0041 affected50 at risk
EG0051 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0081 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0122 affected50 at risk
EG0132 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0241 affected15 at risk
EG0250 affected72 at risk
EG0262 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Drug-induced liver injury
Hepatobiliary disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Drug hypersensitivity
Immune system disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0301 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Borrelia infection
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0301 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Bronchitis
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0032 affected54 at risk
EG0045 affected50 at risk
EG0055 affected52 at risk
EG0063 affected49 at risk
EG0071 affected53 at risk
EG0082 affected51 at risk
EG0092 affected30 at risk
EG0102 affected20 at risk
EG0116 affected51 at risk
EG0126 affected50 at risk
EG0135 affected52 at risk
EG0145 affected49 at risk
EG0153 affected53 at risk
EG0164 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0191 affected19 at risk
EG0202 affected19 at risk
EG0211 affected90 at risk
EG0221 affected89 at risk
EG0232 affected12 at risk
EG0242 affected15 at risk
EG0252 affected72 at risk
EG0262 affected68 at risk
EG0273 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0302 affected12 at risk
EG0313 affected56 at risk
EG0320 affected8 at risk
Conjunctivitis
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0101 affected20 at risk
EG0111 affected51 at risk
EG0122 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Cystitis
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0031 affected54 at risk
EG0043 affected50 at risk
EG0050 affected52 at risk
EG0062 affected49 at risk
EG0072 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0113 affected51 at risk
EG0126 affected50 at risk
EG0130 affected52 at risk
EG0143 affected49 at risk
EG0153 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0202 affected19 at risk
EG0215 affected90 at risk
EG0221 affected89 at risk
EG0232 affected12 at risk
EG0240 affected15 at risk
EG0253 affected72 at risk
EG0261 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0314 affected56 at risk
EG0320 affected8 at risk
Diverticulitis
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0061 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0201 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0301 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Erysipelas
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0081 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0181 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Erythema migrans
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0181 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Eye infection
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0131 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Gastroenteritis
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0002 affected30 at risk
EG0011 affected20 at risk
EG0022 affected51 at risk
EG0031 affected54 at risk
EG0043 affected50 at risk
EG0052 affected52 at risk
EG0064 affected49 at risk
EG0075 affected53 at risk
EG0088 affected51 at risk
EG0092 affected30 at risk
EG0101 affected20 at risk
EG0114 affected51 at risk
EG0124 affected50 at risk
EG0132 affected52 at risk
EG0144 affected49 at risk
EG0155 affected53 at risk
EG0169 affected51 at risk
EG0171 affected18 at risk
EG0180 affected17 at risk
EG0191 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0262 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0301 affected12 at risk
EG0314 affected56 at risk
EG0320 affected8 at risk
Gastroenteritis viral
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0161 affected51 at risk
EG0171 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0231 affected12 at risk
EG0240 affected15 at risk
EG0252 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0301 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Gingival abscess
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0191 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Gingivitis
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0081 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0131 affected52 at risk
EG0140 affected49 at risk
EG0152 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Helicobacter infection
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0073 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0153 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0261 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Herpes ophthalmic
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0181 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Herpes zoster
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0031 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0081 affected51 at risk
EG0092 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0131 affected52 at risk
EG0141 affected49 at risk
EG0152 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0261 affected68 at risk
EG0272 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Hordeolum
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0092 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Influenza
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0002 affected30 at risk
EG0012 affected20 at risk
EG0023 affected51 at risk
EG0033 affected54 at risk
EG0042 affected50 at risk
EG0051 affected52 at risk
EG0061 affected49 at risk
EG0072 affected53 at risk
EG0084 affected51 at risk
EG0095 affected30 at risk
EG0103 affected20 at risk
EG01110 affected51 at risk
EG0127 affected50 at risk
EG0133 affected52 at risk
EG0144 affected49 at risk
EG0155 affected53 at risk
EG0168 affected51 at risk
EG0170 affected18 at risk
EG0181 affected17 at risk
EG0190 affected19 at risk
EG0201 affected19 at risk
EG0212 affected90 at risk
EG0224 affected89 at risk
EG0233 affected12 at risk
EG0241 affected15 at risk
EG0258 affected72 at risk
EG0267 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0302 affected12 at risk
EG0318 affected56 at risk
EG0321 affected8 at risk
Laryngitis
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0032 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0081 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0151 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0201 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Localised infection
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0051 affected52 at risk
EG0061 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0092 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0131 affected52 at risk
EG0142 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Mastitis
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0191 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Nail infection
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Nasopharyngitis
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0004 affected30 at risk
EG0013 affected20 at risk
EG0023 affected51 at risk
EG0034 affected54 at risk
EG00419 affected50 at risk
EG00510 affected52 at risk
EG00613 affected49 at risk
EG0075 affected53 at risk
EG0089 affected51 at risk
EG0098 affected30 at risk
EG0104 affected20 at risk
EG01110 affected51 at risk
EG01220 affected50 at risk
EG01314 affected52 at risk
EG01417 affected49 at risk
EG01510 affected53 at risk
EG01614 affected51 at risk
EG0171 affected18 at risk
EG0181 affected17 at risk
EG0193 affected19 at risk
EG0204 affected19 at risk
EG0217 affected90 at risk
EG02210 affected89 at risk
EG0233 affected12 at risk
EG0243 affected15 at risk
EG0258 affected72 at risk
EG02611 affected68 at risk
EG0274 affected51 at risk
EG0280 affected3 at risk
EG0292 affected11 at risk
EG0302 affected12 at risk
EG0314 affected56 at risk
EG0322 affected8 at risk
Onychomycosis
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0171 affected18 at risk
EG0181 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0241 affected15 at risk
EG0250 affected72 at risk
EG0261 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0301 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Oral fungal infection
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0002 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0092 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0281 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Oral herpes
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0061 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0152 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0241 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Periodontitis
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Pharyngitis
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0051 affected52 at risk
EG0061 affected49 at risk
EG0070 affected53 at risk
EG0081 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0122 affected50 at risk
EG0131 affected52 at risk
EG0143 affected49 at risk
EG0152 affected53 at risk
EG0162 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0261 affected68 at risk
EG0272 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Pharyngitis streptococcal
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0261 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Pneumonia
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0012 affected20 at risk
EG0020 affected51 at risk
EG0031 affected54 at risk
EG0041 affected50 at risk
EG0051 affected52 at risk
EG0061 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0102 affected20 at risk
EG0111 affected51 at risk
EG0122 affected50 at risk
EG0132 affected52 at risk
EG0144 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0171 affected18 at risk
EG0180 affected17 at risk
EG0192 affected19 at risk
EG0201 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0231 affected12 at risk
EG0240 affected15 at risk
EG0253 affected72 at risk
EG0263 affected68 at risk
EG0272 affected51 at risk
EG0280 affected3 at risk
EG0292 affected11 at risk
EG0300 affected12 at risk
EG0312 affected56 at risk
EG0320 affected8 at risk
Pneumonia viral
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Post procedural infection
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0301 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Pulpitis dental
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0231 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Respiratory tract infection
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0122 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0171 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0281 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Rhinitis
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0031 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0062 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0144 affected49 at risk
EG0152 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Sinusitis
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0011 affected20 at risk
EG0021 affected51 at risk
EG0030 affected54 at risk
EG0043 affected50 at risk
EG0050 affected52 at risk
EG0062 affected49 at risk
EG0072 affected53 at risk
EG0082 affected51 at risk
EG0091 affected30 at risk
EG0102 affected20 at risk
EG0113 affected51 at risk
EG0127 affected50 at risk
EG0132 affected52 at risk
EG0144 affected49 at risk
EG0156 affected53 at risk
EG0167 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0212 affected90 at risk
EG0223 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0253 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0281 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Tooth abscess
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0032 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0063 affected49 at risk
EG0070 affected53 at risk
EG0083 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0131 affected52 at risk
EG0143 affected49 at risk
EG0151 affected53 at risk
EG0163 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0241 affected15 at risk
EG0250 affected72 at risk
EG0261 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Tooth infection
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0002 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0061 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0092 affected30 at risk
EG0100 affected20 at risk
EG0112 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0281 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Tracheitis
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0122 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0191 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Upper respiratory tract infection
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0022 affected51 at risk
EG0031 affected54 at risk
EG0044 affected50 at risk
EG0051 affected52 at risk
EG0061 affected49 at risk
EG0070 affected53 at risk
EG0086 affected51 at risk
EG0092 affected30 at risk
EG0100 affected20 at risk
EG0113 affected51 at risk
EG0127 affected50 at risk
EG0133 affected52 at risk
EG0143 affected49 at risk
EG0152 affected53 at risk
EG0168 affected51 at risk
EG0171 affected18 at risk
EG0182 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0254 affected72 at risk
EG0262 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0321 affected8 at risk
Urinary tract infection
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0024 affected51 at risk
EG0033 affected54 at risk
EG0040 affected50 at risk
EG0053 affected52 at risk
EG0063 affected49 at risk
EG0075 affected53 at risk
EG0085 affected51 at risk
EG0093 affected30 at risk
EG0100 affected20 at risk
EG0117 affected51 at risk
EG0125 affected50 at risk
EG0134 affected52 at risk
EG0144 affected49 at risk
EG0159 affected53 at risk
EG0166 affected51 at risk
EG0170 affected18 at risk
EG0181 affected17 at risk
EG0191 affected19 at risk
EG0200 affected19 at risk
EG0215 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0254 affected72 at risk
EG0261 affected68 at risk
EG0276 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0321 affected8 at risk
Vestibular neuronitis
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0201 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Viral infection
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0051 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0081 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0131 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Viral sinusitis
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Viral upper respiratory tract infection
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0181 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0214 affected90 at risk
EG0223 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Vulvovaginal mycotic infection
Infections and infestations
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Alcohol poisoning
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0321 affected8 at risk
Arthropod bite
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0092 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0201 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0253 affected72 at risk
EG0262 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Arthropod sting
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0002 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0092 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Chest injury
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0191 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Contusion
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0004 affected30 at risk
EG0010 affected20 at risk
EG0022 affected51 at risk
EG0031 affected54 at risk
EG0043 affected50 at risk
EG0055 affected52 at risk
EG0061 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0094 affected30 at risk
EG0100 affected20 at risk
EG0112 affected51 at risk
EG0124 affected50 at risk
EG0135 affected52 at risk
EG0143 affected49 at risk
EG0151 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0191 affected19 at risk
EG0201 affected19 at risk
EG0211 affected90 at risk
EG0221 affected89 at risk
EG0231 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0321 affected8 at risk
Eye contusion
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0181 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Fall
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0024 affected51 at risk
EG0031 affected54 at risk
EG0042 affected50 at risk
EG0053 affected52 at risk
EG0062 affected49 at risk
EG0071 affected53 at risk
EG0081 affected51 at risk
EG0092 affected30 at risk
EG0100 affected20 at risk
EG0117 affected51 at risk
EG0124 affected50 at risk
EG0133 affected52 at risk
EG0147 affected49 at risk
EG0153 affected53 at risk
EG0164 affected51 at risk
EG0171 affected18 at risk
EG0180 affected17 at risk
EG0191 affected19 at risk
EG0201 affected19 at risk
EG0213 affected90 at risk
EG0224 affected89 at risk
EG0230 affected12 at risk
EG0241 affected15 at risk
EG0253 affected72 at risk
EG0264 affected68 at risk
EG0270 affected51 at risk
EG0281 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0314 affected56 at risk
EG0322 affected8 at risk
Foot fracture
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0032 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0061 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0122 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0171 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Joint injury
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0131 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0201 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Laceration
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0061 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0092 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0122 affected50 at risk
EG0130 affected52 at risk
EG0144 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0272 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Ligament rupture
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0191 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0261 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Ligament sprain
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0021 affected51 at risk
EG0031 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0083 affected51 at risk
EG0091 affected30 at risk
EG0101 affected20 at risk
EG0111 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0163 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0191 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0231 affected12 at risk
EG0241 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Post procedural contusion
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0042 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0122 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Post procedural haematoma
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0002 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0051 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0092 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0131 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Post procedural haemorrhage
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Procedural pain
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0030 affected54 at risk
EG0042 affected50 at risk
EG0053 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0082 affected51 at risk
EG0092 affected30 at risk
EG0100 affected20 at risk
EG0112 affected51 at risk
EG0124 affected50 at risk
EG0136 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0164 affected51 at risk
EG0172 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0212 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0262 affected68 at risk
EG0274 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0301 affected12 at risk
EG0312 affected56 at risk
EG0320 affected8 at risk
Radius fracture
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0112 affected51 at risk
EG0122 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0201 affected19 at risk
EG0212 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Rib fracture
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0191 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Skin abrasion
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0031 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0081 affected51 at risk
EG0092 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0162 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0191 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Thermal burn
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0081 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Tooth fracture
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0051 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0131 affected52 at risk
EG0141 affected49 at risk
EG0152 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0221 affected89 at risk
EG0231 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Wound
Injury, poisoning and procedural complications
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0051 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0121 affected50 at risk
EG0131 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0191 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Blood calcium increased
Investigations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0031 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0171 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Blood parathyroid hormone increased
Investigations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0321 affected8 at risk
Blood potassium decreased
Investigations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Blood urine present
Investigations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0181 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Cardiac murmur
Investigations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0131 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Weight decreased
Investigations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0081 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0132 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0163 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Weight increased
Investigations
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0082 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0162 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0231 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Dehydration
Metabolism and nutrition disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0051 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0131 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Gout
Metabolism and nutrition disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0181 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Hypercalcaemia
Metabolism and nutrition disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0081 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Hypercholesterolaemia
Metabolism and nutrition disorders
MedDRA 18.1
Systematic Assessment
EG0002 affected30 at risk
EG0010 affected20 at risk
EG0022 affected51 at risk
EG0032 affected54 at risk
EG0042 affected50 at risk
EG0051 affected52 at risk
EG0061 affected49 at risk
EG0070 affected53 at risk
EG0082 affected51 at risk
EG0092 affected30 at risk
EG0101 affected20 at risk
EG0113 affected51 at risk
EG0123 affected50 at risk
EG0131 affected52 at risk
EG0143 affected49 at risk
EG0151 affected53 at risk
EG0164 affected51 at risk
EG0171 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0252 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Hyperglycaemia
Metabolism and nutrition disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0301 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Hyponatraemia
Metabolism and nutrition disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0231 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Insulin resistance
Metabolism and nutrition disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Type 2 diabetes mellitus
Metabolism and nutrition disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0031 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0261 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Arthralgia
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0003 affected30 at risk
EG0010 affected20 at risk
EG0024 affected51 at risk
EG0035 affected54 at risk
EG0048 affected50 at risk
EG0057 affected52 at risk
EG0066 affected49 at risk
EG0075 affected53 at risk
EG0082 affected51 at risk
EG0098 affected30 at risk
EG0103 affected20 at risk
EG01111 affected51 at risk
EG01210 affected50 at risk
EG0138 affected52 at risk
EG0146 affected49 at risk
EG0159 affected53 at risk
EG0166 affected51 at risk
EG0171 affected18 at risk
EG0180 affected17 at risk
EG0191 affected19 at risk
EG0203 affected19 at risk
EG0212 affected90 at risk
EG0226 affected89 at risk
EG0232 affected12 at risk
EG0240 affected15 at risk
EG0256 affected72 at risk
EG02611 affected68 at risk
EG0271 affected51 at risk
EG0281 affected3 at risk
EG0291 affected11 at risk
EG0300 affected12 at risk
EG0318 affected56 at risk
EG0322 affected8 at risk
Arthritis
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0112 affected51 at risk
EG0123 affected50 at risk
EG0131 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0191 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0231 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Back pain
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0002 affected30 at risk
EG0012 affected20 at risk
EG0026 affected51 at risk
EG0033 affected54 at risk
EG0044 affected50 at risk
EG0054 affected52 at risk
EG0067 affected49 at risk
EG0077 affected53 at risk
EG0083 affected51 at risk
EG0097 affected30 at risk
EG0102 affected20 at risk
EG01112 affected51 at risk
EG0128 affected50 at risk
EG0138 affected52 at risk
EG01412 affected49 at risk
EG0159 affected53 at risk
EG0165 affected51 at risk
EG0171 affected18 at risk
EG0181 affected17 at risk
EG0191 affected19 at risk
EG0202 affected19 at risk
EG0211 affected90 at risk
EG0224 affected89 at risk
EG0232 affected12 at risk
EG0240 affected15 at risk
EG0256 affected72 at risk
EG0268 affected68 at risk
EG0272 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0321 affected8 at risk
Bursitis
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0212 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Costochondritis
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0191 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Exostosis
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0002 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0042 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0092 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0122 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Intervertebral disc degeneration
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0181 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0261 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Knee deformity
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Muscle spasms
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0038 affected54 at risk
EG0040 affected50 at risk
EG0052 affected52 at risk
EG0061 affected49 at risk
EG0070 affected53 at risk
EG0083 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0134 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0164 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0223 affected89 at risk
EG0231 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0261 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0301 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Musculoskeletal chest pain
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0022 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0052 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0112 affected51 at risk
EG0122 affected50 at risk
EG0132 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0191 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Musculoskeletal pain
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0002 affected30 at risk
EG0010 affected20 at risk
EG0022 affected51 at risk
EG0032 affected54 at risk
EG0044 affected50 at risk
EG0052 affected52 at risk
EG0062 affected49 at risk
EG0073 affected53 at risk
EG0081 affected51 at risk
EG0093 affected30 at risk
EG0100 affected20 at risk
EG0113 affected51 at risk
EG0128 affected50 at risk
EG0133 affected52 at risk
EG0142 affected49 at risk
EG0154 affected53 at risk
EG0162 affected51 at risk
EG0171 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0201 affected19 at risk
EG0211 affected90 at risk
EG0222 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0252 affected72 at risk
EG0264 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0322 affected8 at risk
Musculoskeletal stiffness
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0042 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0081 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0111 affected51 at risk
EG0124 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0162 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Myalgia
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0002 affected30 at risk
EG0011 affected20 at risk
EG0021 affected51 at risk
EG0031 affected54 at risk
EG0042 affected50 at risk
EG0050 affected52 at risk
EG0061 affected49 at risk
EG0072 affected53 at risk
EG0081 affected51 at risk
EG0094 affected30 at risk
EG0102 affected20 at risk
EG0113 affected51 at risk
EG0123 affected50 at risk
EG0131 affected52 at risk
EG0141 affected49 at risk
EG0152 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0203 affected19 at risk
EG0210 affected90 at risk
EG0222 affected89 at risk
EG0230 affected12 at risk
EG0241 affected15 at risk
EG0252 affected72 at risk
EG0264 affected68 at risk
EG0270 affected51 at risk
EG0281 affected3 at risk
EG0290 affected11 at risk
EG0303 affected12 at risk
EG0317 affected56 at risk
EG0322 affected8 at risk
Neck mass
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0301 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Neck pain
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0031 affected54 at risk
EG0042 affected50 at risk
EG0052 affected52 at risk
EG0061 affected49 at risk
EG0071 affected53 at risk
EG0081 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0113 affected51 at risk
EG0122 affected50 at risk
EG0132 affected52 at risk
EG0142 affected49 at risk
EG0151 affected53 at risk
EG0164 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0201 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Osteoarthritis
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0003 affected30 at risk
EG0011 affected20 at risk
EG0022 affected51 at risk
EG0031 affected54 at risk
EG0041 affected50 at risk
EG0052 affected52 at risk
EG0061 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0095 affected30 at risk
EG0101 affected20 at risk
EG0115 affected51 at risk
EG0122 affected50 at risk
EG0136 affected52 at risk
EG0143 affected49 at risk
EG0155 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0212 affected90 at risk
EG0223 affected89 at risk
EG0231 affected12 at risk
EG0241 affected15 at risk
EG0252 affected72 at risk
EG0261 affected68 at risk
EG0273 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0300 affected12 at risk
EG0315 affected56 at risk
EG0321 affected8 at risk
Pain in extremity
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0003 affected30 at risk
EG0010 affected20 at risk
EG0022 affected51 at risk
EG0035 affected54 at risk
EG00410 affected50 at risk
EG0057 affected52 at risk
EG0065 affected49 at risk
EG0073 affected53 at risk
EG0086 affected51 at risk
EG0094 affected30 at risk
EG0100 affected20 at risk
EG0113 affected51 at risk
EG01212 affected50 at risk
EG0138 affected52 at risk
EG0146 affected49 at risk
EG0155 affected53 at risk
EG0166 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0223 affected89 at risk
EG0231 affected12 at risk
EG0242 affected15 at risk
EG0254 affected72 at risk
EG0262 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0301 affected12 at risk
EG0314 affected56 at risk
EG0321 affected8 at risk
Synovial cyst
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0061 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0092 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Temporomandibular joint syndrome
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0231 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0301 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Tendon disorder
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0112 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0201 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Tendonitis
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0022 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0062 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0112 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0144 affected49 at risk
EG0152 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0201 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0261 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Thoracic spine flattening
Musculoskeletal and connective tissue disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0231 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Basal cell carcinoma
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Benign neoplasm of thyroid gland
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0181 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0261 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Haemangioma of liver
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Lipoma
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0061 affected49 at risk
EG0072 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0152 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0201 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Carotid artery occlusion
Nervous system disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Dizziness
Nervous system disorders
MedDRA 18.1
Systematic Assessment
EG0002 affected30 at risk
EG0011 affected20 at risk
EG0022 affected51 at risk
EG0035 affected54 at risk
EG0043 affected50 at risk
EG0053 affected52 at risk
EG0061 affected49 at risk
EG0071 affected53 at risk
EG0082 affected51 at risk
EG0093 affected30 at risk
EG0102 affected20 at risk
EG0114 affected51 at risk
EG0124 affected50 at risk
EG0136 affected52 at risk
EG0141 affected49 at risk
EG0152 affected53 at risk
EG0164 affected51 at risk
EG0172 affected18 at risk
EG0183 affected17 at risk
EG0190 affected19 at risk
EG0201 affected19 at risk
EG0211 affected90 at risk
EG0222 affected89 at risk
EG0230 affected12 at risk
EG0242 affected15 at risk
EG0253 affected72 at risk
EG0261 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Facial neuralgia
Nervous system disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0201 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Headache
Nervous system disorders
MedDRA 18.1
Systematic Assessment
EG0005 affected30 at risk
EG0013 affected20 at risk
EG0023 affected51 at risk
EG0033 affected54 at risk
EG0043 affected50 at risk
EG0057 affected52 at risk
EG0063 affected49 at risk
EG0073 affected53 at risk
EG0085 affected51 at risk
EG0095 affected30 at risk
EG0103 affected20 at risk
EG0116 affected51 at risk
EG0125 affected50 at risk
EG0138 affected52 at risk
EG0143 affected49 at risk
EG0154 affected53 at risk
EG0167 affected51 at risk
EG0170 affected18 at risk
EG0181 affected17 at risk
EG0191 affected19 at risk
EG0201 affected19 at risk
EG0211 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0241 affected15 at risk
EG0250 affected72 at risk
EG0261 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0300 affected12 at risk
EG0314 affected56 at risk
EG0321 affected8 at risk
Hypoaesthesia
Nervous system disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0051 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0081 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0122 affected50 at risk
EG0131 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Migraine
Nervous system disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0061 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0142 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0241 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Nystagmus
Nervous system disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0241 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Paraesthesia
Nervous system disorders
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0051 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0082 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0122 affected50 at risk
EG0133 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0162 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Restless legs syndrome
Nervous system disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0131 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Sciatica
Nervous system disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0031 affected54 at risk
EG0042 affected50 at risk
EG0051 affected52 at risk
EG0061 affected49 at risk
EG0072 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0113 affected51 at risk
EG0125 affected50 at risk
EG0133 affected52 at risk
EG0141 affected49 at risk
EG0155 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0191 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0221 affected89 at risk
EG0231 affected12 at risk
EG0240 affected15 at risk
EG0253 affected72 at risk
EG0262 affected68 at risk
EG0272 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0301 affected12 at risk
EG0313 affected56 at risk
EG0320 affected8 at risk
Somnolence
Nervous system disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0031 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0231 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Tremor
Nervous system disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0231 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0261 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Anxiety
Psychiatric disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0031 affected54 at risk
EG0042 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0081 affected51 at risk
EG0092 affected30 at risk
EG0100 affected20 at risk
EG0112 affected51 at risk
EG0122 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0151 affected53 at risk
EG0162 affected51 at risk
EG0170 affected18 at risk
EG0181 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0231 affected12 at risk
EG0241 affected15 at risk
EG0250 affected72 at risk
EG0262 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Depression
Psychiatric disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0031 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0101 affected20 at risk
EG0113 affected51 at risk
EG0121 affected50 at risk
EG0131 affected52 at risk
EG0140 affected49 at risk
EG0152 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0261 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0321 affected8 at risk
Disorientation
Psychiatric disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0201 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Insomnia
Psychiatric disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0031 affected54 at risk
EG0044 affected50 at risk
EG0051 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0113 affected51 at risk
EG0124 affected50 at risk
EG0131 affected52 at risk
EG0141 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0201 affected19 at risk
EG0210 affected90 at risk
EG0222 affected89 at risk
EG0230 affected12 at risk
EG0241 affected15 at risk
EG0250 affected72 at risk
EG0261 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Hypercalciuria
Renal and urinary disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0131 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Pollakiuria
Renal and urinary disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0061 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0171 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0201 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Renal cyst
Renal and urinary disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0030 affected54 at risk
EG0042 affected50 at risk
EG0051 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0111 affected51 at risk
EG0122 affected50 at risk
EG0131 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Renal failure
Renal and urinary disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0081 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0181 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Renal impairment
Renal and urinary disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Breast calcifications
Reproductive system and breast disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0241 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Ovarian cyst
Reproductive system and breast disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Vulvovaginal dryness
Reproductive system and breast disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0031 affected54 at risk
EG0042 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0112 affected51 at risk
EG0123 affected50 at risk
EG0130 affected52 at risk
EG0141 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0231 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Cough
Respiratory, thoracic and mediastinal disorders
MedDRA 18.1
Systematic Assessment
EG0002 affected30 at risk
EG0010 affected20 at risk
EG0024 affected51 at risk
EG0030 affected54 at risk
EG0048 affected50 at risk
EG0053 affected52 at risk
EG0064 affected49 at risk
EG0071 affected53 at risk
EG0085 affected51 at risk
EG0093 affected30 at risk
EG0101 affected20 at risk
EG0116 affected51 at risk
EG0128 affected50 at risk
EG0135 affected52 at risk
EG0148 affected49 at risk
EG0153 affected53 at risk
EG0168 affected51 at risk
EG0171 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0201 affected19 at risk
EG0213 affected90 at risk
EG0224 affected89 at risk
EG0232 affected12 at risk
EG0240 affected15 at risk
EG0253 affected72 at risk
EG0263 affected68 at risk
EG0273 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0302 affected12 at risk
EG0314 affected56 at risk
EG0320 affected8 at risk
Epistaxis
Respiratory, thoracic and mediastinal disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0081 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0212 affected90 at risk
EG0222 affected89 at risk
EG0230 affected12 at risk
EG0241 affected15 at risk
EG0250 affected72 at risk
EG0261 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Oropharyngeal pain
Respiratory, thoracic and mediastinal disorders
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0032 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0081 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0162 affected51 at risk
EG0170 affected18 at risk
EG0182 affected17 at risk
EG0191 affected19 at risk
EG0201 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0231 affected12 at risk
EG0240 affected15 at risk
EG0252 affected72 at risk
EG0261 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Rhinitis allergic
Respiratory, thoracic and mediastinal disorders
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0092 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0131 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Cutaneous lupus erythematosus
Skin and subcutaneous tissue disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Dermal cyst
Skin and subcutaneous tissue disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0241 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Dermatitis contact
Skin and subcutaneous tissue disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0081 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0231 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Eczema
Skin and subcutaneous tissue disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0031 affected54 at risk
EG0043 affected50 at risk
EG0051 affected52 at risk
EG0060 affected49 at risk
EG0071 affected53 at risk
EG0081 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0124 affected50 at risk
EG0131 affected52 at risk
EG0140 affected49 at risk
EG0152 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0252 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Erythema
Skin and subcutaneous tissue disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0241 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Night sweats
Skin and subcutaneous tissue disorders
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0081 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0181 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Petechiae
Skin and subcutaneous tissue disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0301 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Pruritus
Skin and subcutaneous tissue disorders
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0030 affected54 at risk
EG0044 affected50 at risk
EG0050 affected52 at risk
EG0062 affected49 at risk
EG0071 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0112 affected51 at risk
EG0124 affected50 at risk
EG0131 affected52 at risk
EG0142 affected49 at risk
EG0152 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0211 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0255 affected72 at risk
EG0262 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Rash
Skin and subcutaneous tissue disorders
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0031 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0061 affected49 at risk
EG0071 affected53 at risk
EG0081 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0122 affected50 at risk
EG0130 affected52 at risk
EG0142 affected49 at risk
EG0151 affected53 at risk
EG0162 affected51 at risk
EG0172 affected18 at risk
EG0181 affected17 at risk
EG0191 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0222 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0263 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Rash pruritic
Skin and subcutaneous tissue disorders
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0021 affected51 at risk
EG0030 affected54 at risk
EG0042 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0092 affected30 at risk
EG0100 affected20 at risk
EG0111 affected51 at risk
EG0122 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0221 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0261 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Skin lesion
Skin and subcutaneous tissue disorders
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0122 affected50 at risk
EG0131 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0191 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Endodontic procedure
Surgical and medical procedures
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Intraocular lens implant
Surgical and medical procedures
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0171 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Tooth extraction
Surgical and medical procedures
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0011 affected20 at risk
EG0021 affected51 at risk
EG0030 affected54 at risk
EG0041 affected50 at risk
EG0050 affected52 at risk
EG0061 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0091 affected30 at risk
EG0101 affected20 at risk
EG0111 affected51 at risk
EG0121 affected50 at risk
EG0130 affected52 at risk
EG0142 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0301 affected12 at risk
EG0311 affected56 at risk
EG0320 affected8 at risk
Tooth repair
Surgical and medical procedures
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0321 affected8 at risk
Deep vein thrombosis
Vascular disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0051 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0131 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Haematoma
Vascular disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0052 affected52 at risk
EG0061 affected49 at risk
EG0070 affected53 at risk
EG0082 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0112 affected51 at risk
EG0121 affected50 at risk
EG0132 affected52 at risk
EG0143 affected49 at risk
EG0151 affected53 at risk
EG0162 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0251 affected72 at risk
EG0261 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Hypertension
Vascular disorders
MedDRA 18.1
Systematic Assessment
EG0001 affected30 at risk
EG0013 affected20 at risk
EG0021 affected51 at risk
EG0032 affected54 at risk
EG0043 affected50 at risk
EG0052 affected52 at risk
EG0062 affected49 at risk
EG0071 affected53 at risk
EG0082 affected51 at risk
EG0091 affected30 at risk
EG0103 affected20 at risk
EG0111 affected51 at risk
EG0124 affected50 at risk
EG0134 affected52 at risk
EG0146 affected49 at risk
EG0153 affected53 at risk
EG0164 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0214 affected90 at risk
EG0223 affected89 at risk
EG0232 affected12 at risk
EG0241 affected15 at risk
EG0253 affected72 at risk
EG0266 affected68 at risk
EG0271 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0321 affected8 at risk
Hypertensive crisis
Vascular disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0231 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0261 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0291 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Hypotension
Vascular disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0031 affected54 at risk
EG0041 affected50 at risk
EG0052 affected52 at risk
EG0061 affected49 at risk
EG0071 affected53 at risk
EG0081 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0122 affected50 at risk
EG0132 affected52 at risk
EG0141 affected49 at risk
EG0151 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0191 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0241 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0272 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Orthostatic hypotension
Vascular disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Peripheral venous disease
Vascular disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0010 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0081 affected51 at risk
EG0090 affected30 at risk
EG0100 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0161 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0301 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Phlebitis
Vascular disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0050 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0130 affected52 at risk
EG0140 affected49 at risk
EG0150 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
Phlebitis superficial
Vascular disorders
MedDRA 18.1
Systematic Assessment
EG0000 affected30 at risk
EG0011 affected20 at risk
EG0020 affected51 at risk
EG0030 affected54 at risk
EG0040 affected50 at risk
EG0051 affected52 at risk
EG0060 affected49 at risk
EG0070 affected53 at risk
EG0080 affected51 at risk
EG0090 affected30 at risk
EG0101 affected20 at risk
EG0110 affected51 at risk
EG0120 affected50 at risk
EG0131 affected52 at risk
EG0140 affected49 at risk
EG0151 affected53 at risk
EG0160 affected51 at risk
EG0170 affected18 at risk
EG0180 affected17 at risk
EG0190 affected19 at risk
EG0200 affected19 at risk
EG0210 affected90 at risk
EG0220 affected89 at risk
EG0230 affected12 at risk
EG0240 affected15 at risk
EG0250 affected72 at risk
EG0260 affected68 at risk
EG0270 affected51 at risk
EG0280 affected3 at risk
EG0290 affected11 at risk
EG0300 affected12 at risk
EG0310 affected56 at risk
EG0320 affected8 at risk
OTHER
Results Disclosure Restriction on PI(s)?
Yes
Other Details
The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.
D010024
Osteoporosis
D010281
Parathyroid Hormone
D036361
Peptide Hormones
D006728
Hormones
D006730
Hormones, Hormone Substitutes, and Hormone Antagonists